

EFFECTS OF COTININE AND NICOTINE ON CHROMAFFIN CELL SIGNALLING

Petri J. Vainio

Department of Pharmacology and Toxicology
Institute of Biomedicine
University of Helsinki

Academic dissertation

*To be presented, with the assent of the Faculty of Medicine of the University of Helsinki,
for public examination in the small auditorium of the Department of Pharmacology
and Toxicology, Siltavuorenpenger 10 A, on September 30th 2000, at 12 noon.*

Helsinki 2000

Supervised by:

Professor Raimo K. Tuominen
Division of Pharmacology and Toxicology
Department of Pharmacy
University of Helsinki, Finland


Reviewed by:

Docent Hannu Kankaanranta
Department of Pharmacology
Medical School
University of Tampere, Finland;
Department of Respiratory Medicine
Tampere University Hospital, Finland


and

Docent Hannu Komulainen
Laboratory of Toxicology
Division of Environmental Health
National Public Health Institute
Kuopio, Finland

Nicotine:



Cotinine:



ISBN 952-91-2542-9

ISBN 952-91-2543-7 (PDF version <http://ethesis.helsinki.fi>)

ISBN 952-91-2544-5 (html version <http://ethesis.helsinki.fi>)

Helsinki 2000, Yliopistopaino

CONTENTS

List of original publications	4
Abbreviations	4
Introduction	5
Review of the literature	6
Pharmacokinetics of nicotine and cotinine	6
Nicotinic acetylcholine receptors and their ligands	7
Nicotine signalling.....	11
Signalling through phospholipase C and phospholipase D.....	12
Calcium signalling.....	14
Protein kinase C	15
Bovine adrenal chromaffin cells.....	17
Cotinine pharmacology.....	17
Aims of the study	19
Materials and methods	20
Cell culture.....	20
PLD sample preparation and assay.....	20
Western blot.....	21
Protein assay.....	21
[³ H]Noradrenaline release.....	21
Measurement of [Ca ⁺⁺] _i	21
Cytotoxicity test.....	22
PKC assay	22
[³ H]Phorbol-12,13-dibutyrate binding	22
Animals	23
Receptor binding	23
Chemicals.....	23
Data analysis	23
Results	24
PLD in chromaffin cell signalling	24
Cotinine effects on chromaffin cells	25
Cotinine binding to nicotinic acetylcholine receptors	26
Discussion	27
Methodological considerations	27
Phospholipase D in chromaffin cell nicotinic responses	28
Cotinine pharmacology.....	29
Conclusions	32
Acknowledgements	33
References	34

LIST OF ORIGINAL PUBLICATIONS

This thesis is based on the following original publications, which are referred to in the text by Roman numerals (I – VI):

- I Vainio PJ, Somerharju P, Jaakkola T, Tuominen RK. Receptor-stimulated phospholipase D activity in bovine adrenal chromaffin cells. *Neurosci Res Commun* 1999, 24: 179-185.
- II Vainio PJ, Tuominen RK. Nicotine-evoked exocytosis from bovine chromaffin cells is independent of phospholipase D activation. *Neurosci Res Commun* 2000, 26: 93-101.
- III Vainio PJ, Viluksela M, Tuominen RK. Inhibition of nicotinic responses by cotinine in bovine adrenal chromaffin cells. *Pharmacol Toxicol* 1998, 83: 188–193.
- IV Vainio PJ, Viluksela M, Tuominen RK. Nicotine-like effects of cotinine on protein kinase C activity and noradrenaline release in bovine adrenal chromaffin cells. *J Auton Pharmacol* 1998, 18: 245–250.
- V Vainio PJ, Törnquist K, Tuominen RK. Cotinine and nicotine inhibit each other's calcium responses in chromaffin cells. *Toxicol Appl Pharmacol* 2000, 163: 183-187.
- VI Vainio PJ, Tuominen RK. Cotinine binding to nicotinic acetylcholine receptors in bovine chromaffin cell and rat brain membranes. A submitted manuscript.

ABBREVIATIONS

[Ca ⁺⁺] _i	intracellular free Ca ⁺⁺ concentration
DMPP	1, 1-dimethyl-4-phenylpiperazinium
EGTA	ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid
HEPES	N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
PKC	protein kinase C
-cPKC	conventional PKC isoenzyme; Ca ⁺⁺ - and diacylglycerol-dependent
-nPKC	novel PKC isoenzyme; diacylglycerol-dependent, Ca ⁺⁺ -independent
-aPKC	atypical PKC isoenzyme; Ca ⁺⁺ - and diacylglycerol-independent
PLA ₂	phospholipase A ₂
PLC	phospholipase C
-PC-PLC	phosphatidylcholine-specific PLC
-PI-PLC	phosphatidylinositol-specific PLC
PLD	phospholipase D
PMA	phorbol-12-myristate-13-acetate (12-tetradecanoylphorbol-13-acetate)

INTRODUCTION

Tobacco smoking has been an important social habit in American cultures since the prehistoric era. In the later half of this millennium, tobacco use has spread to nearly all communities. In addition to smoking, tobacco has been used as chewing tobacco, and as dry nasal and wetted oral snuff. Among the thousands of chemicals contained in fermented tobacco products, nicotine is the substance causing addiction (see Hoffmann and Wynder, 1986).

Besides being a drug of abuse, nicotine is a frequently used model compound in studies involving cholinergic neurotransmission. The nicotine effects are mediated through nicotinic acetylcholine receptors that are found both in the periphery and the central nervous system. Upon binding to its receptor, nicotine opens an integral non-selective cation channel. This leads to cell depolarisation and induces various responses. Acutely, for example, nicotine evokes transmitter release, while a sustained nicotine exposure upregulates enzymes involved in synthesis of catecholamine transmitters (Stachowiak *et al.*, 1990).

Nicotine itself is not a major health hazard, but consumption of tobacco, especially smoking, has often been regarded as the single most important preventable cause of death and serious diseases (Hoffmann and Wynder, 1986). Thus, alternative ways of nicotine administration have been developed for smoking cessation. These include nicotine gum, patches, nasal spray, vapour inhaler, sublingual tablets and lozenges (Leischow and Cook, 1999).

No matter how nicotine is used, it is metabolised in the body. Cotinine is the major metabolite of nicotine. It is eliminated much slower than the parent compound, and in chronic nicotine administration its concentrations are much higher than those of nicotine (Benowitz and Jacob, 1999). Cotinine has frequently been considered biologically inactive (Benowitz, 1996), although some of its effects have been known for nearly four decades (Borzelleca *et al.*, 1962). Depending on the model, cotinine has caused effects both similar to and opposite to those of nicotine. Cotinine passes the blood-brain barrier, and thus can participate in the central effects of nicotine administration (Paulson and Olson, 1995). Only few data on the effects of cotinine at the cellular level have been published.

Sustained changes in protein phosphorylation status and protein kinase activities can participate in various events, such as transmitter synthesis (Stachowiak *et al.*, 1990) and memory formation (Izquierdo, 1994; Micheau and Riedel, 1999). In bovine adrenal chromaffin cells, nicotine causes a prolonged increase in diacylglycerol levels and protein kinase C (PKC) activity (Tuominen *et al.*, 1992). The primary catalyst of diglyceride production, phosphatidylinositol-specific phospholipase C (PI-PLC), participates only in acute responses due to a rapid negative feedback. Thus, the enzymes more likely responsible for prolonged diacylglycerol production are phosphatidylcholine-specific phospholipase C (PC-PLC) and phospholipase D (PLD) (Liscovitch, 1992; Nishizuka, 1995). The existence of the former is uncertain. PLD has also been claimed to be lacking from bovine chromaffin cells (Purkiss *et al.*, 1991).

In this study, I have used bovine adrenal chromaffin cells as a model of neural cells. The research focus has been on the role of PLD in nicotinic pharmacology and on the effects of cotinine on nicotinic responses and cell signalling.

REVIEW OF THE LITERATURE

PHARMACOKINETICS OF NICOTINE AND COTININE

The rewarding effect of nicotine depends on liberation and absorption pharmacokinetics of the dosage form. The more rapidly the brain, or arterial, concentration peaks, the more intense is the pharmacological response. At physiological pH, approximately one quarter of nicotine is present in uncharged form and is thus prone to pass through lipid membranes (Anonymous, 1991; Budavari *et al.*, 1996). Since nicotine is a base, alkaline tobacco products, such as snuff, chewing tobacco and cigars, favour its absorption, which has been demonstrated for cigar smoke as compared with cigarette smoke (Armitage and Turner, 1970).

With cigarette smoking, nicotine reaches the brain in less than 20 seconds, and the blood nicotine concentration increases for the duration of the smoking period. Use of oral snuff or chewing tobacco yields peak blood levels comparable with those achieved by smoking. However, they take approximately half an hour to occur due to thicker barriers at the site of nicotine absorption (Benowitz *et al.*, 1988). Immediately after smoking a cigarette, the arterial nicotine concentration is over two-fold higher than the venous concentration. Nicotine plasma levels in smokers are typically around 200 nM and they never exceed 1 μ M (Benowitz and Jacob, 1984; Moreyra *et al.*, 1992; Gourlay and Benowitz, 1997).

Pharmaceutical preparations used in smoking cessation, including chewing gum, transdermal patches, sublingual tablets, lozenges and vapour inhalers, release nicotine slower than cigarette smoking, thereby avoiding rapid peaks. Nasal spray pharmacokinetics are somewhat more comparable with smoking. However, no alternative route of nicotine administration yields as high nicotine peaks as quickly as cigarette smoking (Benowitz *et al.*, 1988; Mulligan *et al.*, 1990; Hurt *et al.*, 1993, 1998; Gourlay and Benowitz, 1997; Schuh *et al.*, 1997).

Nicotine is rapidly and widely distributed in the body. It accumulates in the stomach, bladder, kidneys and salivary glands. Nicotine is eliminated mainly by hepatic metabolism, with a typical elimination half-life of 2 h. Approximately 80 % of nicotine is C-oxidised, mainly by cytochrome P450 2A6, followed by aldehyde oxidase, yielding cotinine. In addition, nicotine may undergo pyrrolidine N-demethylation and N-oxidation, as well as pyridine N-methylation and N-glucuronidation (Figure 1). One tenth of the nicotine is excreted as such by the kidneys. As a weak base, nicotine can be trapped in an acidic environment, and its renal clearance can be enhanced five-fold by urine acidification (Benowitz *et al.*, 1983, 1994; Anonymous, 1991; Yamazaki *et al.*, 1999).

Cotinine is less lipophilic than nicotine. It distributes to the total body water. Upon nicotine infusion to rats, the highest cotinine concentrations are present in the kidneys, followed by the lung and the liver. In the brain, the cotinine level somewhat exceeds the arterial concentration. Interestingly, when cotinine is infused, the tissue cotinine concentration reaches the arterial concentration only in the kidneys (Gabrielsson and Bondesson, 1987). Cotinine has been detected in the brain of experimental animals and in the cerebrospinal fluid of smokers (Paulson and Olson, 1995; Crooks *et al.*, 1997). However, in a positron emission tomography study, cotinine penetration through the blood-brain barrier was not observed (Halldin *et al.*, 1992). Yet, the brain cotinine is probably of peripheral origin, since no evidence for nicotine C-oxidation in the brain has been found (Hansson and Schmitterl w, 1965; Crooks *et al.*, 1997).




FIGURE 1. The main metabolic pathways of nicotine. The relative amount of the metabolites in the urine is displayed as percentages.

Cotinine is eliminated relatively slowly with a typical half-life of 15 – 20 h (Benowitz *et al.*, 1983; Curvall *et al.*, 1990). In the venous blood of smokers, the steady-state cotinine concentration is higher than the peak nicotine concentration, typically 3 – 4 μM (Benowitz *et al.*, 1983; Benowitz and Jacob, 1994). Cotinine is not a metabolic end product (Figure 1). One sixth is excreted in the urine as such, and the rest is metabolised in the liver via both the phase I functionalisation reactions and the phase II conjugation reactions. At least pyridine N-methylation, N-glucuronidation and N-oxidation, hydroxylation of the pyrrolidine ring at two different sites, and pyrrolidine N-demethylation are known to occur (Byrd *et al.*, 1992; Benowitz *et al.*, 1994). Due to its relatively slow elimination and tendency to accumulate, cotinine could affect biological systems if it possessed even minor affinity for nicotinic receptors.

NICOTINIC ACETYLCHOLINE RECEPTORS AND THEIR LIGANDS

RECEPTORS

Studies of nicotine effects on muscle led John Newport Langley to suggest the existence of a receptive substance nearly one hundred years ago (Langley, 1905). Later, the nicotinic receptor was the first to be sequenced, cloned and gene-sequenced (Noda *et al.*, 1982, 1983a, 1983b; Claudio *et al.*, 1983). Assistance in reaching these milestones was provided by the electric eel *Electrophorus* and the electric ray *Torpedo* species, whose electric organs express a large number of nicotinic acetylcholine receptors. Furthermore, the electric organ nicotinic receptor protein was relatively easy to purify by affinity chromatography utilising α -bungarotoxin (see Lindstrom, 1999).

The nicotinic acetylcholine receptors are pentameric ion channels. Each of the subunits spans the membrane four times and all subunits contribute to channel formation. To date, genes encoding 16 different subunits of the vertebrate nicotinic receptors have been cloned. These subunits are identified as $\alpha 1 - \alpha 9$, $\beta 1 - \beta 4$, γ , δ and ϵ . The subunits present in adult neuromuscular junction are $\alpha 1$, $\beta 1$, ϵ and δ . In the foetal muscle, γ subunit replaces ϵ , as is also the case in electric organs. Outside the neuromuscular junction, $\alpha 2 - \alpha 6$ and $\beta 2 - \beta 4$ are thought to form the heteropentameric receptors with both α and β subunits. Subunits $\alpha 7 - \alpha 9$ form the usually homomeric non- β receptors. The heteropentameric neuronal receptors are frequently presented as

consisting of two α and three β subunits. However, neither the subunit stoichiometry nor the arrangement of most of the receptors are known with certainty. Furthermore, it is unclear whether all subunits are naturally expressed in functional combinations (see Sargent, 1993; McGehee and Role, 1995; Lukas *et al.*, 1999). Besides the central and the peripheral nervous systems and sensory organs, neuronal nicotinic receptors are reportedly expressed in lymphocytes, granulocytes, fibroblasts, chondrocytes, spermatozoa, placenta and pulmonary neuroendocrine cells (see Lukas *et al.*, 1999).

The nomenclature of nicotinic acetylcholine receptors has not been established. The historical classification of nicotinic receptors to neuronal (ganglionic-type, C6, N_N, N₁) and muscle (C10, N_M, N₂) receptors (Watson and Girdlestone, 1993) ceased nearly a decade ago. After that, various terms have been used to identify receptor types (Watson and Girdlestone, 1995; Watling, 1998; Alexander and Peters, 1999). Reflecting the difficulty of creating a satisfying nomenclature, the IUPHAR compendium of receptor classification provides no information on nicotinic acetylcholine receptor (IUPHAR Committee on Receptor Nomenclature and Drug Classification, 1998). Recently, however, the subcommittee on nicotinic acetylcholine receptors has recommended a classification based on the subunits forming the receptors (Lukas *et al.*, 1999). The subunit types and their stoichiometry are expressed if known. If only some of the subunits forming the receptor in question are known, the identified subunits are enumerated and an asterisk added to indicate that additional subunit types may exist.

According to the recommended classification, the adult muscle nicotinic acetylcholine receptor type is $(\alpha 1)_2\beta 1\epsilon\delta$, and the foetal muscle and electric organ receptor type is $(\alpha 1)_2\beta 1\gamma\delta$. Autonomic ganglion receptors may be called $\alpha 3\alpha 5\beta 2\beta 4$, $\alpha 3\alpha 5\beta 4$, $\alpha 3\beta 4$, $\alpha 3\beta 4^*$, $\alpha 3^*$ or $\alpha 7^*$ receptors, depending on their composition. In the central nervous system, the major combination is $(\alpha 4)_2(\beta 2)_3$, and other receptors expressed include $\alpha 4\alpha 5\beta 2$, $\alpha 7^*$ and $\alpha 9^*$ receptors. In the cerebellum, $\alpha 3\beta 2\beta 3\beta 4$ and $\alpha 3\beta 2\beta 4\beta 5$ combinations have also been demonstrated. The $\alpha 8$ subunit is expressed in avian retinas, and hitherto has only been observed in chicks.

AGONISTS

The natural ligand of nicotinic receptors is acetylcholine. Other agonists include nicotine, 1,1-dimethyl-4-phenylpiperazinium (DMPP), cytisine, epibatidine and numerous novel ligands developed by the pharmaceutical industry. However, many of the compounds regarded as agonists are partial agonists in certain models. Indeed, despite being called nicotinic receptors, many of the natural receptors respond to nicotine as to a partial agonist. Properties of selected nicotinic agonists are presented in Table 1.

The clinical use of nicotine has been limited to treating withdrawal symptoms upon smoking cessation. In the near future, nicotinic agonists may get new clinical indications. Thus far, they have proven effective in preclinical or early clinical studies for relieving pain and cognitive disorders, as well as symptoms of parkinsonism, Tourette's syndrome and schizophrenia (see Decker and Arneric, 1999; Donnelly-Roberts and Brioni, 1999; Flores and Hargreaves, 1999; Leonard *et al.*, 1999; Levin *et al.*, 1999; Menzaghi *et al.*, 1999).

In receptor-binding studies utilising various nicotinic receptor agonists, both apparent one-site binding and apparent two-site binding have been reported. The high-affinity binding is considered to represent ligand binding to the desensitised receptors, while the low-affinity binding occurs at the ground-state receptors. Nevertheless, the differ-

ent binding affinities may also represent different receptor populations. Mathematical modelling of the binding data is further complicated by the fact that opening of a cholinergic receptor channel requires binding of two agonist molecules to the pentamer and that the agonist sites may cooperate (see Haylett, 1996; Gotti *et al.*, 1997).

TABLE 1. Characteristics of nicotinic acetylcholine receptor agonists

Ligand (source)	Affinity for receptors^a	References^b
A-85380	rat forebrain: K _i 97 pM	Xiao <i>et al.</i> , 1998
ABT-418	brain heteropentameric: K _i 3 nM	Arneric <i>et al.</i> , 1994
acetylcholine (endogenous)	K _i : α2β2: 2 nM, α3β2 & α4β2: 30 nM, α4β4: 70 nM, α2β4 100 nM, α3β4: 560 nM	Parker <i>et al.</i> , 1998
anabaseine (<i>Aphaenogaster</i> sp. ant; <i>Paranemertes</i> sp. worm)	K _i : α7: 32 nM, α4β2: 32 nM, fish muscle: 210 nM	Kem <i>et al.</i> , 1997
anabasine (tobacco)	K _i : α2β2: 14 nM, α3β2: 57 nM, α7: 58 nM, α4β2: 76–260 nM, α4β4: 370 nM, α2β4: 450 nM, α3β4: 2.1 μM, fish muscle: 7.2 μM	Kem <i>et al.</i> , 1997; Parker <i>et al.</i> , 1998
anatoxin-a (cyanobacterium <i>Anabaena flos-aquae</i>)	K _i : rat forebrain 6.5 nM, α3β4: 53 nM	Thomas <i>et al.</i> , 1993; Xiao <i>et al.</i> , 1998
carbachol	K _i : rat forebrain 428 nM, α3β4: 3.8 μM; resistant to cholinesterase	Xiao <i>et al.</i> , 1998
choline (endogenous)	α4β2:K _i 110 μM but induces no current; α7: full agonist with 2.3 mM EC ₅₀ (current)	Papke <i>et al.</i> , 1996; Alkondon <i>et al.</i> , 2000
cytisine (e.g. <i>Laburnum anagyroides</i>)	K _i : α2β2: 380 pM, α4β2: 990 pM, α4β4: 1.2 nM, α2β4: 4.9 nM, α3β2: 14 nM, α3β4: 56–200 nM; weak at bovine β4	Campos-Caro <i>et al.</i> , 1997; Parker <i>et al.</i> , 1998; Xiao <i>et al.</i> , 1998
dimethylaminocinnamylidene DMPP	K _i : α7: 34 nM, α4β2: 350 nM	de Fiebre <i>et al.</i> , 1995
epibatidine (frog <i>Epipedobates tricolor</i>)	K _i : β2-containing: 10–50 nM, β4-containing: ca. 1 μM; guanethidine-like activity	Birmingham and Wilson, 1965; Parker <i>et al.</i> , 1998
GTS-21	α7-selective partial agonist: K _i 310 nM, EC ₅₀ ca. 100 μM (current); has an active metabolite	Badio and Daly, 1994; Gerzanich <i>et al.</i> , 1995
lobeline (tobacco)	K _i : α2β2: 2.6 nM; α4β2: 4 nM; α3β2: 13 nM; α4β4: 49 nM; α2β4: 220 nM; α3β4: 480 nM	Damaj <i>et al.</i> , 1997; Parker <i>et al.</i> , 1998
nicotine (tobacco)	K _i : α2β2: 800 pM; α4β2: 4–5 nM; α3β2: 16 nM; α4β4: 26 nM; α2β4: 70 nM; α3β4: 300–500 nM; α7: 400 nM; fish muscle: 1.4 μM	Kem <i>et al.</i> , 1997; Parker <i>et al.</i> , 1998; Xiao <i>et al.</i> , 1998
RJR-2403	K _i : α4β2: 26 nM, α7: 36 μM	Bencherif <i>et al.</i> , 1996
SIB-1508Y	neuronal, weak at α3β4, inactive at α7; rat brain estimated K _i 3–10 nM	Cosford <i>et al.</i> , 1996
SIB-1553A	prefers β4; in rat brain estimated K _i 0.3–1 μM	Vernier <i>et al.</i> , 1999
SIB-1765F	α4β2-selective; K _i : α4β2: 7.5 nM, α4β4: 235 nM	Sacaan <i>et al.</i> , 1997
tetramethylammonium	K _i : α4β2: 260–480 nM	Papke <i>et al.</i> , 1996; Whiteaker <i>et al.</i> , 1998

^aEC₅₀: concentration causing half-maximal stimulation (studied parameter in parentheses)

^bGeneral references: (McGehee and Role, 1995; Vizi *et al.*, 1995; Adams and Swanson, 1996; Budavari *et al.*, 1996; Gotti *et al.*, 1997; Alexander and Peters, 1999)

ANTAGONISTS

As with most receptors and receptor families, several antagonists recognise closely related receptors with different affinities. However, most of the nicotinic acetylcholine receptor subtypes lack highly selective antagonists. Nicotinic antagonists may block the acetylcholine binding site, they may affect the agonist affinity state of the receptor, or they may block the integral ion channel itself (Alexander and Peters, 1999).

Since development of various antihypertensive agents by the pharmaceutical industry, neuronal nicotinic antagonists have not been used much in clinical practice. However, promising results have been obtained in relieving Tourette's syndrome with mecamylamine (Sanberg *et al.*, 1998), and muscle nicotinic receptor antagonists such as rocuronium, vekuronium and mivacurium, are used in anaesthetic practice to sustain skeletal muscle relaxation. Despite their limited use in humans, neuronal nicotinic receptor antagonists are important tools in pharmacological and toxicological research. Properties of selected nicotinic antagonists are listed in Table 2.

TABLE 2. Characteristics of nicotinic antagonists

Ligand (source)	Affinity for receptors^a	References^b
atropine (<i>Atropa belladonna</i>)	$\alpha 9$: IC ₅₀ 1.3 μ M (10 μ M acetylcholine)	Elgoyhen <i>et al.</i> , 1994
α -bungarotoxin (krait <i>Bungarus multicinctus</i>)	IC ₅₀ : muscle, $\alpha 7$, $\alpha 8$, $\alpha 9$: 0.5 – 10 nM; inactive at neuronal heteromers	Motomura <i>et al.</i> , 1992; López <i>et al.</i> , 1998
κ -bungarotoxin (<i>B. multicinctus</i>)	K _i : $\alpha 3\beta 2$: 10 nM; muscle, $\alpha 3\beta 2$: low micromolar	Luetje <i>et al.</i> , 1990
chlorisondamine (synthetic)	neuronal channel blocker: micromolar	El-Bizri and Clarke, 1994
α -conotoxins GI, GIA, GII, MI, SI, SIA, SII (snails <i>Conus spp.</i>)	muscle: IC ₅₀ 10 – 100 nM (100 and 500 nM acetylcholine)	Luetje <i>et al.</i> , 1990; Johnson <i>et al.</i> , 1995
α -conotoxin IMI (<i>C. imperialis</i>)	IC ₅₀ : $\alpha 7$: 0.22 μ M (500 μ M acetylcholine); $\alpha 9$: 1.8 μ M (100 μ M acetylcholine)	Johnson <i>et al.</i> , 1995
α -conotoxin MII (<i>C. magus</i>)	IC ₅₀ : $\alpha 3\beta 2$ 0.5 nM (300 μ M acetylcholine)	Cartier <i>et al.</i> , 1996
decamethonium (synthetic)	IC ₅₀ micromolar, weak partial agonist	
dihydro- β -erythroidine (seeds of <i>Erythrina spp.</i>)	K _i : $\alpha 3\beta 4$: 220 μ M; rat brain: 29 μ M	Xiao <i>et al.</i> , 1998
gallamine (synthetic)	brain: K _i ca. 100 μ M; muscle IC ₅₀ 8 μ M (electrical stimulation)	Törocsik <i>et al.</i> , 1989; Fletcher and Steinbach, 1996
hexamethonium (synthetic)	neuronal channel blocker; $\alpha 3\beta 4$: IC ₅₀ ca. 200 μ M (100 μ M nicotine)	Xiao <i>et al.</i> , 1998
histrionicotoxin (frog <i>Dendrobates histrionicus</i>)	IC ₅₀ : $\alpha 3\beta 4^*$: 3 μ M (0.3 mM carbachol); muscle: micromolar	Wada <i>et al.</i> , 1989
lophotoxin (corals <i>Lophogorgia spp.</i>)	K _i : muscle, $\beta 2$ -containing receptors: ca. 10 μ M; irreversible	Luetje <i>et al.</i> , 1990
mecamylamine (synthetic)	$\beta 4$ -containing receptors IC ₅₀ ca. 1 μ M (20 – 200 μ M nicotine); channel blocker	Stauderman <i>et al.</i> , 1998; Xiao <i>et al.</i> , 1998
methyllycaconitine (<i>Delphinium brownii</i> seeds)	K _i : $\alpha 7$: ca. 1 nM; neuronal: 4–6 μ M	Ward <i>et al.</i> , 1990; Whiteaker <i>et al.</i> , 1998
muscarine (mushrooms <i>Clitocybe spp.</i> , <i>Inocybe spp.</i>)	$\alpha 9$: IC ₅₀ 75 μ M (10 μ M acetylcholine)	Elgoyhen <i>et al.</i> , 1994
neosurugatoxin (Japanese ivory mollusc <i>Babylonia japonica</i>)	IC ₅₀ : $\alpha 3\beta 4^*$: 27 nM (0.3 mM carbachol); $\beta 2$ -containing receptors: low nanomolar; muscle: ca. 100 nM (100 nM ACh)	Wada <i>et al.</i> , 1989; Luetje <i>et al.</i> , 1990
nereistoxin (annelid <i>Lumbriconereis heteropoda</i>)	muscle, neuronal; chick retina: IC ₅₀ 3.5 μ M (0.3 mM DMPP)	Xie <i>et al.</i> , 1993; Xie <i>et al.</i> , 1996
nicotine (tobacco)	IC ₅₀ : $\alpha 9$: 30 μ M (10 μ M acetylcholine)	Elgoyhen <i>et al.</i> , 1994
strychnine (nut <i>Strychnos nux-vomica</i>)	IC ₅₀ : $\alpha 9$: 20 nM (10 μ M acetylcholine); muscle, $\alpha 2\beta 2$, $\alpha 2\beta 4$: micromolar	Elgoyhen <i>et al.</i> , 1994; García-Colunga and Miledi, 1999
tubocurarine (<i>Chondodendron tomentosum</i> stems)	muscle, neuronal: K _i micromolar	Xiao <i>et al.</i> , 1998

^aIC₅₀: concentration causing half-maximal inhibition (stimulus in parentheses)

^bGeneral references: (Deneris *et al.*, 1991; McGehee and Role, 1995; Vizi *et al.*, 1995; Adams and Swanson, 1996; Budavari *et al.*, 1996; Gotti *et al.*, 1997; Alexander and Peters, 1999)

NICOTINE SIGNALLING

Nicotinic acetylcholine receptors are ligand-gated cation channels. Binding of two agonist molecules on the pentamer stabilises the channel open-state. The activated receptors non-selectively conduct cations. The overall conductance as well as the relative conductances of various ions depend on the subunit composition of the receptor (see Lindstrom *et al.*, 1995; McGehee and Role, 1995; Ramirez-Latorre *et al.*, 1999). Receptor-carried Ca^{++} alone may increase the intracellular free Ca^{++} concentration ($[\text{Ca}^{++}]_i$) sufficiently to evoke responses (Zhou and Neher, 1993). However, usually membrane depolarisation and a secondary Ca^{++} influx through voltage-operated channels follow nicotinic activation.

A rapid increase in $[\text{Ca}^{++}]_i$ activates various intracellular processes, such as transmitter and neuropeptide release and activation of phospholipase A_2 (PLA_2). The events are not unique to nicotinic stimulation, but occur upon membrane depolarisation in general (Livett *et al.*, 1981; Holz *et al.*, 1982; Frye and Holz, 1984). The rapid increase in $[\text{Ca}^{++}]_i$ also activates phospholipase C (PLC), generating diacylglycerol which, in turn, activates PKC (TerBush and Holz, 1986; Eberhard and Holz, 1987; TerBush *et al.*, 1988). Despite generally being accompanied and modulated by kinase activation, transmitter exocytosis can also occur in its absence (TerBush and Holz, 1990).

The agonists act not only by stabilising the receptor open-state thus causing activation, but also by evoking desensitisation. Desensitisation, by definition, refers to a situation, where the decline in response, either fade or tachyphylaxis, involves the receptor itself or is a direct consequence of receptor activation (Jenkinson *et al.*, 1998). Although nicotinic receptors may be in several un-, mono- and diliganded conformations, relatively simple models on activation-desensitisation cycles can be presented due to the low probability of certain conformational changes (Katz and Thesleff, 1957; Auerbach and Akk, 1998). The desensitisation is mainly thought to occur in diliganded state, and the recovery through ligand dissociation (Figure 2).




FIGURE 2. A two-gate model of nicotinic receptor activation and desensitisation (Auerbach and Akk, 1998). R represents the receptor and A_2 the two bound agonists. C and D represent the closed states of the putative activation and desensitisation gates. Thus, the ion channel is conductive only in conformation RA_2 . No monoliganded states are presented because of their low probability of undergoing desensitisation or recovering from it.

Desensitisation also seems to occur without a preceding activation, not in full agreement with the simplified models. The receptor function is frequently desensitised at a lower concentration than that required for activation, in particular during prolonged exposures. Thus, whether a nicotinic agonist evokes or inhibits cholinergic responses depends not only on the subunit composition of the receptor in question, but also on the length of the exposure and the concentration of the agonist (Riker, 1968; Marks *et al.*, 1996; Marks, 1999). Indeed, the nicotine concentrations reached while smoking more closely resemble receptor-desensitising concentrations than activating concentrations. Thus, it is tempting to believe that at least some of the common nicotine effects would be mediated by receptor desensitisation instead of activation. This is supported by the ability of mecamylamine to relieve symptoms of Tourette's syndrome.

SIGNALLING THROUGH PHOSPHOLIPASE C AND PHOSPHOLIPASE D

Phospholipases are enzymes that hydrolyse ester bonds of various phospholipids. The mammalian phospholipases are PLA₂, PLC and PLD, which are named after the linkages they cleave (Figure 3A). The primary glycerol-based products of PLC and PLD, diacylglycerol and phosphatidic acid, can be interconverted by diacylglycerol kinase and phosphatidic acid phosphohydrolase (Figure 3B).




FIGURE 3. A: Bonds hydrolysed by phospholipases A₂ (PLA₂), C (PLC) and D (PLD). R₁ and R₂ represent esterified fatty acids, e.g. oleic, palmitic, or arachidonic acid. R₃ represents the polar head of the phospholipid, e.g. choline or inositol 4,5-bisphosphate. B: Interconversion of phosphatidic acid (PA), and diacylglycerol (DG), generated by PLD and phosphatidylinositol-specific PLC (PI-PLC). DGK: diacylglycerol kinase; PAP: phosphatidic acid phosphohydrolase; PC: phosphatidylcholine; PI-4,5-P₂: phosphatidylinositol 4,5-bisphosphate; I-1,4,5-P₃: inositol-1,4,5-trisphosphate.

PHOSPHOLIPASE C

PLC can be divided into two major categories according to substrate specificity: PI-PLC and PC-PLC. PI-PLC is divided into PLC β , PLC γ and PLC δ subclasses, all of which have isoenzymes identified by Arabic numerals (see Singer *et al.*, 1997; Bairoch and Apweiler, 1999). Although mammalian PC-PLC has not been cloned, an abundance of data suggests its existence (Cook and Wakelam, 1992; Nofer *et al.*, 1997).

PLC β and PLC δ enzymes are regulated by heterotrimeric G proteins. In the classical activation pathway, PLC β interacts with the α subunits of G_q proteins (Smrcka *et al.*, 1991; Hepler *et al.*, 1993). In addition, the G protein $\beta\gamma$ subunits stimulate PLC β , albeit not as effectively as the α subunits (Hepler *et al.*, 1993; Gudermann *et al.*, 1996). PLC δ is stimulated by the α subunits of G_h proteins (Feng *et al.*, 1996), whereas PLC γ is activated by growth factors probably via tyrosine phosphorylation (see Singer *et al.*, 1997; Lynn and Hughes, 2000).

Inositol lipid hydrolysis can be stimulated by increasing [Ca⁺⁺]_i, without prior activation of G-protein-coupled or tyrosine kinase receptors (Eberhard and Holz, 1987, 1991). Although inositol lipids are required for Ca⁺⁺-stimulated exocytosis, PI-PLC activity and hydrolysis are not necessary (Eberhard *et al.*, 1990).

In addition to diacylglycerol, which activates the conventional and novel PKC isoenzymes (see below), PI-PLC activity yields inositol 1,4,5-trisphosphate. It acts on specific endoplasmic reticular receptors, thus evoking Ca⁺⁺ release. Ca⁺⁺, in turn, is an

important intracellular messenger affecting transmitter release and the recovery of nicotinic receptors from desensitisation, as well as the activity of various other ion channels and enzymes (see Berridge, 1993; Fenster *et al.*, 1999).

Stimulation of PLC β -linked receptors leads to a biphasic diglyceride production. While the early phase is accompanied by inositol trisphosphate formation, the later phase is not, suggesting that PI-PLC activation is transient (Griendling *et al.*, 1986; Wright *et al.*, 1988; Fukami and Takenawa, 1989). Sustained diglyceride formation can be catalysed by a sequential action of PLD and phosphatidic acid phosphohydrolase (Martinson *et al.*, 1990), or by a putative PC-PLC (Cook and Wakelam, 1992). Furthermore, a direct PKC activation by phorbol esters or synthetic diglycerides inhibits the early phase of diglyceride formation by PLC β , without affecting the later phase (Griendling *et al.*, 1986; Portilla *et al.*, 1988; Tilly *et al.*, 1990).

PHOSPHOLIPASE D

PLD activity was initially observed in plants more than fifty years ago. Nearly thirty years later, it was detected in mammalian tissues, first in the rat brain (Saito and Kanfer, 1975). Thereafter, PLD has been demonstrated in virtually all mammalian cells and tissues studied (Meier *et al.*, 1999). Bovine adrenal chromaffin cells have been claimed to be an exception, and whether they possess PLD activity is under debate (Purkiss *et al.*, 1991; García *et al.*, 1992; Caumont *et al.*, 1998; Glenn *et al.*, 1998).

The first mammalian PLD was cloned and characterised relatively late (Hammond *et al.*, 1995). The enzyme exists in two alternatively spliced forms, PLD1a and PLD1b (Hammond *et al.*, 1997). A distinct PLD isoenzyme, PLD2, has also been cloned. It is constitutively active and appears to be regulated mainly by inhibition (Colley *et al.*, 1997; Kodaki and Yamashita, 1997). There is also evidence suggesting that at least one more type, dependent on oleic acid but independent of phosphoinositides, remains to be cloned (Massenburg *et al.*, 1994; Okamura and Yamashita, 1994; Frohman *et al.*, 1999). Some structural and regulatory properties of cloned PLDs and oleate-dependent PLD activity are summarised in Table 3.

TABLE 3. Characteristics of phospholipase D enzymes and activities

	PLD1a, PLD1b	PLD2	Oleate-dependent PLD
Size	124 kDa (a), 119 kDa (b)	106 kDa	190 kDa ^a
Preferred membranes	Golgi membranes, microsomes, endosomes	plasma membrane	plasma membrane, nucleus, microsomes
Cytosolic	probably	possibly	no
Basal activity	low	high	low
Activation by			
*lipids	PIP2, PIP3 ^b	PIP2, PIP3	oleate, arachidonate
*GTPases	Arf, RhoA, Rac, Cdc42	minor ^c	no
*kinases	cPKC α , β ; nPKC ϵ	no	no
Inhibitory proteins	synaptojanin, fodrin, AP3	synaptojanin, synuclein	not known
Other inhibitors	oleate, primary alcohols, ceramides	oleate, primary alcohols	primary alcohols

References: (Okamura and Yamashita, 1994; Colley *et al.*, 1997; Exton, 1997; Hammond *et al.*, 1997; Kodaki and Yamashita, 1997; Morris *et al.*, 1997b; Brown *et al.*, 1998; Katayama *et al.*, 1998; Lopez *et al.*, 1998; Frohman *et al.*, 1999; Houle and Bourgoin, 1999)

^asize approximated from electrophoresis gels
^bPIP2: phosphatidylinositol 4,5-bisphosphate,
 PIP3: phosphatidylinositol 3,4,5-trisphosphate
^cArf reportedly activates a truncated PLD2

A full activation of PLD1 requires the presence of Arf, RhoA, active PKC and inositol phospholipids. However, neither phosphorylation nor phosphoinositidase activity is necessary. Since the effects of the above-mentioned activators are synergistic, it is probable that each has a separate regulatory binding site on the enzyme (see Singer *et al.*, 1996, 1997; Morris *et al.*, 1997b).

A number of extracellular signals that act through tyrosine kinase receptors or G_q family proteins and PKC, increase PLD activity. Examples include angiotensin II, bradykinin, choline esters, insulin, and phorbol esters (Qian and Drewes, 1989; Horwitz, 1991; Purkiss *et al.*, 1991; Horwitz and Ricanati, 1992; Kanoh *et al.*, 1992; Standaert *et al.*, 1996; Jung *et al.*, 1998). Effects of nicotinic agonists and cell depolarisation by high extracellular potassium on PLD activity are less clear (Caumont *et al.*, 1998; Glenn *et al.*, 1998; Singh *et al.*, 1998).

PLD and PLD-produced phosphatidic acid have been suggested to have a role in various phenomena. Clearly, PLD alters membrane composition and physical properties by hydrolysing phosphatidylcholine to phosphatidic acid. The released choline is not known to serve intracellular signalling functions, but can be used as a substrate in acetylcholine synthesis. PLD has a role in exocytosis for example from neutrophils and mast cells, but it does not appear to be necessary for the process in all cell types (Glenn *et al.*, 1998; Jones *et al.*, 1999). Importantly, diglyceride generation from phosphatidic acid by phosphatidic acid phosphohydrolase may in part be responsible for sustained PKC activation (Liscovitch, 1992; Nishizuka, 1995). PLD and phosphatidic acid have a mitogenic effect on multiplying cells (Boarder, 1994; Venable and Obeid, 1999). Phosphatidic acid may also directly participate in PKC activation, and may enhance the receptor-mediated PLC activation (see English *et al.*, 1996). Furthermore, it selectively activates a putative dual specificity protein kinase (McPhail *et al.*, 1999). Phosphatidic acid can be converted to lysophosphatidic acid by PLA₂ to stimulate cell proliferation, tissue regeneration and transmitter release via G_q- and G_i-coupled receptors and to enhance PKC activation (see Moolenaar, 1995; Nishizuka, 1995).

CALCIUM SIGNALLING

In resting cells, the [Ca⁺⁺]_i is usually around or below 100 nM. Plasma membrane and smooth endoplasmic reticulum Ca⁺⁺ pumps, plasma membrane Na⁺/Ca⁺⁺ antiporter as well as mitochondrial Ca⁺⁺ carriers extrude Ca⁺⁺ from the cytosol and hence participate in sustaining the low [Ca⁺⁺]_i and terminating Ca⁺⁺ signals (Alberts *et al.*, 1994).

Various mechanisms are involved in the entry of extracellular Ca⁺⁺ into the cytosol. Ca⁺⁺ may enter a cell through Ca⁺⁺-carrying transmitter receptors, such as nicotinic acetylcholine receptors and NMDA glutamate receptors. Store-operated Ca⁺⁺ channels are opened in response to emptied intracellular Ca⁺⁺ stores, and they are responsible for capacitative calcium entry. The mechanism is unknown, but protein-protein interactions may be involved (Berridge *et al.*, 1998). Voltage-operated Ca⁺⁺ channels are opened upon membrane depolarisation. They are classified according to activation threshold, kinetics, conductivity and pharmacology to L-, T-, N-, P-, Q- and R-type channels. The L- and T-type channels are found in several cell types while the rest of the channel types appear neuronal (see Trist and Spedding, 1998; Watling, 1998).

Ca⁺⁺ may be released to the cytosol also from endoplasmic reticular stores. Two receptor-operated release pathways are known. Inositol 1,4,5-trisphosphate receptors are

activated by PLC-generated inositol 1,4,5-trisphosphate. Ryanodine receptors are activated by caffeine, ryanodine and their putative physiological agonist cyclic adenosine diphosphate ribose. These endoplasmic reticular receptors are sensitised by Ca^{++} , and they mediate calcium-induced Ca^{++} release (Berridge, 1998).

Changes in the $[\text{Ca}^{++}]_i$ are detected by various proteins including calmodulin, troponin C, annexins, cPKCs and ion channels. Hence, it regulates a multitude of cell events from fertilisation to cell death. It is a crucial relay pathway controlling cytoskeletal organisation, contraction, secretion including transmitter release, many metabolic functions, proliferation and apoptosis (see Berridge *et al.*, 1998).

PROTEIN KINASE C

REGULATION

PKC was originally identified as a proteolytically activated protein kinase with no obvious function in signal transduction (Inoue *et al.*, 1977; Takai *et al.*, 1977). Soon it was realised that it was a calcium-activated enzyme with absolute phospholipid dependence and great diacylglycerol sensitivity (for early reviews, see Nishizuka, 1984, 1986). After less than a decade, however, it became evident that PKC is not a single entity, but rather a family of serine-threonine kinases (Coussens *et al.*, 1986; Parker *et al.*, 1986). Moreover, calcium- and diglyceride-independent isoenzymes were detected (Ohno *et al.*, 1988; Ono *et al.*, 1988, 1989; Schaap *et al.*, 1989). Indeed, the differences in activation requirements have led to confusions in nomenclature. Upon uncovering the structure and basic biochemistry of mouse PKC μ , it was first named protein kinase D (Valverde *et al.*, 1994), and even today both of these names are used.

In mammals, eleven protein kinase C isoenzymes have been identified (Bairoch and Apweiler, 1999). The conventional isoenzymes (cPKC α , - β 1, - β 2 and - γ) require Ca^{++} and diacylglycerol for activation. The novel isoenzymes (nPKC δ , - ϵ , - η , - θ and - μ) are Ca^{++} -independent but still diacylglycerol-dependent. The atypical isoenzymes (aPKC ζ and - ι) need neither diglyceride nor Ca^{++} for activation. Conventional PKC β 1 and - β 2 are alternative splicing products of a single gene, while distinct genes code the rest of the isoenzymes (Mellor and Parker, 1998; Ron and Kazanietz, 1999).

In addition to the conventional lipid regulators of PKC, namely phosphatidylserine and diacylglycerols, free *cis*-unsaturated fatty acids and some phosphatidylcholine species have an activity-enhancing effect on cPKC isoenzymes (Shinomura *et al.*, 1991; Burns and Bell, 1992; Ron and Kazanietz, 1999). Phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate activate the n- and aPKCs (Nakanishi *et al.*, 1993; Singh *et al.*, 1993). Phosphatidic acid and ceramide can also activate aPKC ζ (English *et al.*, 1996; Galve-Roperh *et al.*, 1997; Wang *et al.*, 1999).

In the resting state, PKC is cytosolic and a pseudosubstrate domain occupies the catalytic site. Upon enzyme activation, Ca^{++} permits cPKC isoenzymes to associate with membranes. The membrane-associated PKC is then inserted into the membrane, the pseudosubstrate leaves the catalytic site and the kinase is activated. Diacylglycerol is required for membrane insertion of c- and nPKCs. Activation of aPKCs is less well understood (Burns and Bell, 1992; Keranen and Newton, 1997; Ron and Kazanietz, 1999).

A great number of stimuli, especially those acting through receptors coupled to PLC and phosphatidylinositol bisphosphate hydrolysis, transiently activate PKC. PKC is

also the major receptor for tumour-promoting phorbol esters which bind to the diglyceride site of the enzyme (see Parker, 1992). A prolonged increase in the membrane-bound, *i.e.* the active, PKC accompanied with an increased level of diglycerides can be evoked by phorbol esters and by the cell membrane receptor agonists nicotine and angiotensin II (Tuominen *et al.*, 1991; Tuominen *et al.*, 1992; Tuominen *et al.*, 1993).

Phorbol esters not only activate PKC, but upon prolonged exposure, they cause down-regulation of PKC protein and activity (Rodriguez-Pena and Rozengurt, 1984). This is due to increased proteolysis of the membrane-associated enzyme by proteases, such as calpain. Initially, a constitutive kinase activity is generated as the regulatory lipid-binding domain is separated from the catalytic one. However, the final net effect is a reduced PKC activity. This phenomenon also provides a widely used tool for studying PKC-dependence of signal transduction (see Parker, 1992; Rasmussen *et al.*, 1992).

FUNCTION

Similar to various other protein kinases, PKC plays a role in signal amplification from cell surface through kinase cascades to the nucleus. It also participates in the fine-tuning of cellular events (Figure 4). In addition to other kinases, PKC phosphorylation targets include other enzymes, structural proteins, ion channels and receptors (Aderem and Seyrkora, 1992; Borner and Fabbro, 1992; Jaken, 1992; Knox and Kaczmarek, 1992). PKC can directly interact with a variety of proteins, not all of them PKC substrates, an important example being PLD1 (see Ron and Kazanietz, 1999).




FIGURE 4. A simplified model of the interplay of phospholipases C (PLC) and D (PLD), protein kinase C (PKC), and free intracellular Ca⁺⁺ ([Ca⁺⁺]_i). PC: phosphatidylcholine, PA: phosphatidic acid, PIP₂: phosphatidylinositol 4,5-bisphosphate, DG: diglyceride, IP₃: inositol 1,4,5-trisphosphate, subscripts i: inactive, a: active. Closed head arrow indicates an activating effect and closed circle an inhibitory effect on adjacent signalling pathways.

PKC-catalysed phosphorylation of nicotinic acetylcholine receptors has been reported to enhance the receptor recovery from desensitisation in rat chromaffin cells and in *Xenopus* oocytes expressing $\alpha 4\beta 2$ receptors, as well as to reduce the deepness of desensitisation of the $\alpha 4\beta 2$ receptors (Khiroug *et al.*, 1998; Fenster *et al.*, 1999). However, in voltage-clamped chick sympathetic ganglion neurons, PKC activators enhance nicotinic receptor current decay (Downing and Role, 1987). Moreover, an increased number of human $\alpha 4\beta 2$ receptors in a cell line have been noted in response to a prolonged exposure to PMA but not to PKC inhibitors (Gopalakrishnan *et al.*, 1997), suggesting PKC-enhanced desensitisation and thus concurring with previous views (Huganir and Greengard, 1990; Swope *et al.*, 1992). Yet, dephosphorylated nicotinic receptors have been suggested to be a signal for inhibiting receptor turnover (Peng *et al.*, 1994).

BOVINE ADRENAL CHROMAFFIN CELLS

Adrenal medulla originates from the embryonic neural crest and functionally resembles a sympathetic ganglion. In the 1960's, a method for isolating and culturing gerbil adrenal chromaffin cells was established (Douglas *et al.*, 1967a, 1967b). In the 1970's, bovine chromaffin cell cultures were developed (Schneider *et al.*, 1977), and within a decade several laboratories adopted and further elaborated these methods (Kilpatrick *et al.*, 1980; Unsicker and Müller, 1981; Waymire *et al.*, 1983; Wilson, 1987). During this period, chromaffin cells, especially of bovine origin, became a widely used tool in neurochemical and neurobiological studies (see Livett, 1984).

Bovine adrenal chromaffin cells synthesise noradrenaline and adrenaline. The cells also have a high-affinity uptake mechanism for catecholamines (Kenigsberg and Trifaró, 1980). Upon nicotinic stimulation and increased $[Ca^{++}]_i$, the chromaffin cells quantally secrete not only catecholamines but also peptides, such as enkephalin (Livett *et al.*, 1981). Bovine adrenal chromaffin cells retain their neural properties in culture for prolonged periods, whether or not they were allowed to attach to the culture dish (Kilpatrick *et al.*, 1980; Waymire *et al.*, 1983).

Although the muscarinic receptors of cultured bovine chromaffin cells are coupled to phosphoinositide hydrolysis (Eberhard and Holz, 1987; Nakaki *et al.*, 1988), their activation evokes only weak if any secretion of catecholamines (Ballesta *et al.*, 1989; Cheek *et al.*, 1989; McKay *et al.*, 1991; Yamagami *et al.*, 1991). Thus, cholinergic effects on these cells are almost purely nicotinic, in contrast to porcine (Nassar-Gentina *et al.*, 1997) and feline chromaffin cells (Ballesta *et al.*, 1989).

Similar to sympathetic ganglion cells in general, bovine chromaffin cells express nicotinic acetylcholine receptors. In these cells, genes encoding the $\alpha 3$, $\alpha 5$, $\alpha 7$ and $\beta 4$, but not the $\beta 2$, nicotinic acetylcholine receptor subunits are expressed (Criado *et al.*, 1992; García-Guzmán *et al.*, 1995; Campos-Caro *et al.*, 1997; Wenger *et al.*, 1997). Hence, the possible subunit combinations are $\alpha 3\beta 4^*$ with or without an $\alpha 5$ subunit, and $\alpha 7$.

Stimulation of nicotinic acetylcholine receptors on bovine adrenal chromaffin cells leads to Na^+ influx and depolarisation of the plasma membrane. Then $[Ca^{++}]_i$ is increased, PLA_2 is activated, and transmitters are released (Holz *et al.*, 1982; Frye and Holz, 1984). Although the secretory events are accompanied by inositol phospholipid breakdown and PKC activation (TerBush and Holz, 1986; Eberhard and Holz, 1987; TerBush *et al.*, 1988), and direct PKC activation by phorbol esters can evoke exocytosis, changes in PI-PLC and PKC activity are not necessary for catecholamine secretion (TerBush and Holz, 1990; Loneragan *et al.*, 1996).

COTININE PHARMACOLOGY

Cotinine structure and synthesis have been known for more than one-hundred years (Pinner, 1893). Cotinine has mainly been considered a pharmacologically inert metabolite of its psychoactive parent compound (Jaffe, 1990; Anonymous, 1991; Benowitz, 1996; Rang *et al.*, 1999). However, already in the early sixties, the first evidence of possible cotinine activity was published. The compound was found to be hypotensive and to abolish the nicotine-induced vasopressor response in dogs (Borzelleca *et al.*, 1962). Cotinine was also found to have effects opposite to nicotine, first as a rabbit and rat intestinal smooth muscle relaxant (Kim *et al.*, 1968).

Cotinine was then reported to counteract the catecholamine decreases secondary to tyrosine hydroxylase inhibition in the rat (Eneroth *et al.*, 1977). The same group further reported a nicotine-like reduction in 5-hydroxytryptamine turnover by cotinine in the rat brain. The effects of nicotine on the central nervous system were speculated to be in part mediated by cotinine, independently of nicotinic acetylcholine receptors (Fuxe *et al.*, 1979). In mice, cotinine has been reported to mimic nicotine as an antinociceptive compound (Erenmemisoglu and Tekol, 1994) and in counteracting ethanol-induced incoordination (Dar *et al.*, 1994). Recently, a cotinine-evoked dopamine release from rat striatal slices has been reported (Dwoskin *et al.*, 1999). In humans, cotinine slightly worsens nicotine withdrawal symptoms (Keenan *et al.*, 1994), and it eliminates the beneficial effects of a nicotine patch (Hatsukami *et al.*, 1998).

Outside the nervous system, cotinine has been reported to affect eicosanoid release both in a nicotine-like manner (Saareks *et al.*, 1993) and differently from nicotine (Chahine *et al.*, 1990). Moreover, in steroid metabolism both nicotine-like (Patterson *et al.*, 1990) and nicotine-unlike effects (Andersson *et al.*, 1993) have been detected.

Although cotinine has been nearly or totally inert in receptor binding assays (Abood *et al.*, 1983, 1985), it seemingly has pharmacological activity. The question arises as to whether biological activity of cotinine is mediated through nicotinic acetylcholine receptors; by activation, desensitisation or blockade.

AIMS OF THE STUDY

As outlined in the previous section, cotinine pharmacologically acts on neural systems, but its effects remain obscure. Since cotinine is structurally related to nicotine, its probable targets include nicotinic receptors, through which it can modify nicotinic responses. PLD, in turn, is a good candidate for catalysing the nicotine-evoked prolonged diglyceride production and sustaining the increased PKC activity. The finding – presented in a single report at the time this work was planned – that PLD is lacking from bovine chromaffin cells does not concur with this hypothesis. If PLD activity exists in chromaffin cells, it may well have a role in nicotinic signalling.

The aim of the present study was to clarify whether:

- 1 receptor-linked PLD activity exists in bovine adrenal chromaffin cells;
- 2 PLD participates in nicotine signalling, especially in sustained kinase activation;
- 3 cotinine modulates the effects of nicotine on intracellular (PKC activity, $[Ca^{++}]_i$) and intercellular (noradrenaline release) chromaffin cell signalling;
- 4 cotinine itself evokes chromaffin cell responses; and
- 5 cotinine effects are mediated by nicotinic acetylcholine receptors.

MATERIALS AND METHODS

CELL CULTURE

Bovine adrenal glands were obtained from local slaughterhouses. They were carried to the laboratory chilled in an ice bath. The medullae were digested by retrograde perfusion through the central vein with collagenase B (Roche Molecular Biochemicals / Boehringer Mannheim Biochemicals, Mannheim, Germany), and the medullary suspension was purified by centrifugation through a meglumine diatrizoate – sodium diatrizoate gradient (made in the laboratory, or available commercially as Urografin® from Schering AG, Berlin, Germany). Purification was continued by differential plating in tissue culture flasks for two to three hours. The cells were plated on appropriate dishes or plates (Wilson and Viveros, 1981; Waymire *et al.*, 1983; Wilson, 1987; Tuominen *et al.*, 1991), grown in standard medium (Dulbecco's modified Eagle's medium/Ham's nutrient mixture F12 with 10% foetal calf serum and antibiotics), and used within a week of preparing the culture. The cultures yielded 10 – 120 x 10⁶ cells per gland. Despite differences in cell yield, cultures were consistently of ≥ 90% purity as estimated by neutral red staining.

PLD SAMPLE PREPARATION AND ASSAY

The cells were labelled with [³H]oleic acid or [³H]myristic acid (both from Amersham, Buckinghamshire, UK) for 24 h. They were then washed with isotonic saline and gently suspended in an appropriate buffer (pH 7.4 at 37°C): based on bicarbonate (5% CO₂ atmosphere) or on N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES, room air). The assay was based on a PLD-catalysed characteristic reaction, where primary alcohol replaces water in accepting the phosphatidyl moiety. The phosphatidylalcohol thus formed is more stable than phosphatidic acid and can be used as a measure of PLD activity (see Morris *et al.*, 1997a). Hence, the cells were exposed to stimulants in the presence of 50 mM n-butanol (I) or 220 mM ethanol (II). In 1-h exposures, the alcohol was present for the last 15 min.

The lipids were extracted with chloroform : methanol : water (10 : 10 : 9, by volume), acidified with HCl (Bligh and Dyer, 1959). The chloroform phase was collected, the solvent was evaporated, and the lipid residue was redissolved in chloroform : methanol (9 : 1). The phospholipids were then separated by thin layer chromatography (LK6D plates from Whatman, Clifton, NJ, USA). The solvent used for phosphatidylbutanol separation was the upper phase of ethylacetate : isoctane : acetic acid : water (13 : 2 : 3 : 10) (Liscovitch and Amsterdam, 1989). When phosphatidylethanol was formed, oxalate-coated thin layer chromatography plates were used with a chloroform : methanol : acetic acid : water (75 : 45 : 3 : 1) mixture as the solvent (Horwitz, 1991; Caumont *et al.*, 1998). Phosphatidylalcohol markers were run along with the samples. The phospholipids on chromatography plates were stained with iodine.

Phosphatidylethanol and phosphatidylbutanol standards were prepared from 1-palmitoyl-2-oleyl phosphatidylcholine (Avanti Polar Lipids, Alabaster, AL, USA) by *Streptomyces sp.* PLD (Sigma, St. Louis, MO, USA), as previously described (Eibl and Kovatchev, 1981; Kobayashi and Kanfer, 1987; Comfurius *et al.*, 1990). A two-phase system consisting of 50 ml l⁻¹ n-butanol or ethanol, 450 ml l⁻¹ chloroform, and 500 ml l⁻¹ 185 mM Tris buffer (pH 7.4) with 185 mM CaCl₂, was used. The mixture was shaken for 2 – 4 h at 37°C. The lipids were extracted as above (Bligh and Dyer, 1959).

WESTERN BLOT

The cultured cells were washed and homogenised by sonication in the presence of protease inhibitors phenylmethylsulfonyl fluoride 1 mM and leupeptin 250 $\mu\text{g ml}^{-1}$. The protein extracts were prepared by high-acceleration centrifugation (100 000 x g, 45 – 60 min), first in the absence and then in the presence of 0.1% Triton X-100 to extract the soluble and membrane proteins, respectively. The extracts were denatured, and the protein samples were separated in 8% polyacrylamide gels (Laemmli, 1970) and transferred to nitrocellulose membranes (Schleicher & Shüll, Dassel, Germany) by semi-dry electroblotting (SemiPhor™, Hoefer Pharmacia Biotech, San Fransisco, CA, USA). The membranes were blocked in 5% fat-free milk, exposed to antibodies, and the immunoreactive proteins were detected by enhanced chemiluminescence reaction (Durrant, 1990; Crisp and Dunn, 1994).

Rabbit anti-rat PKC antisera were a generous gift from Dr. William C. Wetsel (NIEHS, NC, USA). They were raised against carboxyterminal peptides of PKC isoenzymes as follows: SYVNPQFVHPILQSAV (α), SYTNPEFVINV (β 1), SFVNSEFLKPE-VKS (β 2), DARSPTSPVPVPVM (γ), SFVNPKYEQFLE (δ), KGFSYFGEDLMP (ϵ), EYINPLLLSAEESV (ζ), and their preparation and properties have previously been described (Wetsel *et al.*, 1992). Anti-PLD antibody, against sequence CIIGSANINERS, was a product of Upstate Biotechnology, Lake Placid, NY, USA. Goat anti-rabbit secondary antibody was purchased from Bio-Rad Laboratories, CA, USA.

PROTEIN ASSAY

The protein concentrations of the extracts were determined according to Bradford (1976). The dye reagent was either commercial (III, IV; Bio-Rad, Richmond, CA, USA), or it was prepared from Serva Blue G (I, VI; Serva, Heidelberg, Germany). The protein standards were prepared from bovine serum albumin concentrate (Pierce, Rockford, IL, USA).

[³H]NORADRENALINE RELEASE

The experiments were run largely as previously described (McKay and Schneider, 1984), in saline buffered with HEPES and NaHCO_3 (pH 7.4 at 5% CO_2). Ascorbic acid 1 mg ml^{-1} was added to the medium to avoid oxidation of the catecholamines. To get a lower non-specific release, 1 mg ml^{-1} bovine serum albumin was added in some experiments (II, IV). The cell catecholamine pools were labelled with 500 nM [³H]noradrenaline (Amersham, 22 kBq ml^{-1}) for 10 min (II, IV) or 60 min (III). Then, the cells were washed and exposed to stimulants as indicated. The treatments were terminated by pipetting the medium into scintillation vials or plates. The cells were disrupted in 0.1% Triton X-100 before transferring them to scintillation vials or plates. Results are expressed as percentages of total cellular [³H]noradrenaline contents released.

MEASUREMENT OF $[\text{Ca}^{++}]_i$

The cells were washed and gently resuspended in experiment buffer (NaCl 118 mM, KCl 5 mM, MgSO_4 1 mM, CaCl_2 1 mM, HEPES 20 mM, glucose 10 mM, pH 7.4). The cells were labelled with 5 μM Fura 2-AM (Molecular Probes, Eugene, OR, USA) for the first 10 min, and then with 500 nM Fura 2-AM for an additional hour (McMillian *et al.*, 1992). Then, the cells were washed, incubated for at least 10 min and washed again. All the incubations were performed in the dark to avoid photobleaching. For ex-

periments in a Ca^{++} -free environment, CaCl_2 was omitted from the experiment buffer and 100 μM ethylene glycol-bis(β -aminoethylether)- N,N,N',N' -tetraacetic acid (EGTA) was added. Measurements were performed at room temperature in a quartz cuvette (2×10^6 cells/ml), with a Hitachi F2000 fluorometer essentially as previously described (Törnquist *et al.*, 1999). The excitation wavelengths were 340 nm and 380 nm, and the emission wavelength was 510 nm. $[\text{Ca}^{++}]_i$ was calculated as previously described (Grynkiewicz *et al.*, 1985), using a software designed for the fluorometer. The K_d value for Fura 2 was 224 nM.

CYTOTOXICITY TEST

The cells were exposed to the test compounds for the desired time. In the 24-hour experiments, 0.5 mg ml⁻¹ 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma, St. Louis, MO, USA) was added three hours before stopping the treatment. In short experiments, MTT was present throughout the incubation. For measuring toxicity, media were aspirated and replaced with dimethyl sulfoxide. After shaking for 5 min, the absorbances were read at 540 nm to estimate the MTT reduction. The extent of reduction was considered as a measure of mitochondrial function and cell survival (Supino, 1990).

PKC ASSAY

Standard methods (Kikkawa *et al.*, 1983; Roskoski, 1983), with some modifications (Tuominen *et al.*, 1991), were used. Treatments were stopped by washing the cells with ice-cold Ca^{++} -free medium (pH 7.5). Cells were disrupted by sonication. The suspension was centrifuged (100 000 \times g, 60 min, 4°C), first without (soluble extract) and then with (particulate extract) 1 ml l⁻¹ Triton X-100. In the assay, the protein extracts were allowed to catalyse histone (0.3 mg ml⁻¹ calf thymus histone type III-S; Sigma) phosphorylation for 5 min at 30°C in the presence of adenosine γ -³²P-triphosphate (Amersham), both with and without the PKC activators: 1 mM CaCl_2 , 40 μg ml⁻¹ phosphatidylserine and 8 μg ml⁻¹ 1,2-sn-dioctanoylglycerol. The reaction was terminated by spotting reaction mixture onto P81 phosphocellulose paper (Whatman, Maidstone, UK), and washing the papers in 75 mM phosphoric acid. The trapped radioactivity was counted after air-drying. PKC activity was calculated by subtracting the non-specific activity from total activity. Results are expressed as nmoles of inorganic phosphate incorporated into histone min⁻¹ mg⁻¹ of protein.

[³H]PHORBOL-12,13-DIBUTYRATE BINDING

For short treatments, the growing medium was replaced by HEPES- and NaHCO_3 -buffered saline (pH 7.4 at 5% CO_2), and the cells were allowed to stabilise for 60 min. [³H]Phorbol-12,13-dibutyrate (PDBu, Amersham) with (non-specific binding) or without (total binding) 1 μM phorbol 12-myristate 13-acetate (PMA) was added into the wells. The 24-h experiments were run in the growing medium, and 15 min before stopping the treatment [³H]PDBu with or without PMA was added. The final concentration of [³H]PDBu was 10 nM. Treatments were terminated by washing the cells with isotonic saline. The bound radioactivity was measured, and results are expressed as specific binding.

ANIMALS

Adult female Wistar rats (HsdBrlHan:WIST) with free access to food and water were used. Brains were obtained after decapitation, and brain areas were dissected on ice. The study protocol was approved by the University of Helsinki ethics committee for animal experiments.

RECEPTOR BINDING

Tissues and cells were homogenised in a glass-teflon homogeniser in hypotonic Tris buffer containing protease inhibitors. The homogenates were spun twice at 30 000 x g for 15 min, and the pellets were resuspended in fresh buffer. [³H]Epibatidine (NEN Life Science Products, Boston, MA, USA) was used as the nicotinic label. The experiments were performed in polypropene tubes in 50 mM Tris HCl buffer (pH 7.4) at 37°C. The binding time was 4 h. To determine non-specific binding, 300 µM nicotine was added to the incubations. In saturation binding experiments, the [³H]epibatidine concentration was 14.5 pM – 6.75 nM (chromaffin cells) or 10 pM – 2.15 nM (brain). In competition experiments, single concentrations of 100 pM (chromaffin cells) and 250 pM (brain) were used. The incubations were terminated by using Brandell M-24R cell harvester. The bound ligand was trapped in Whatman GF/B filters presoaked for five hours in 5 mg ml⁻¹ polyethyleneimine, and the filters were washed three times with cold Tris buffer. The filters were counted for radioactivity after overnight incubation in the scintillation liquid.

CHEMICALS

If not otherwise stated, the chemicals were obtained from standard commercial sources. Inorganic salts and solvents were of analysis grade and were supplied by Merck, Darmstadt, Germany and by J.T. Baker, Deventer, The Netherlands. The pharmacological agents and the cell culture media were mostly from Sigma, St. Louis, MO, USA. Other suppliers included Tocris Cookson, Bristol, UK; Alomone Labs, Jerusalem, Israel; and LC Services, Woburn, MA, USA.

DATA ANALYSIS

Arithmetic means, standard deviations and standard errors of means were calculated from the numeric data. Parametric tests were preferred whenever data distribution allowed. Angular transformation for percentage data was done if required to homogenise the variances (IV). In comparing two groups with a dependent variable, paired t-test was used (V).

Primarily, analysis of variance was used for estimating the existence of differences. Repeated measures tests were used where appropriate (II, V). *Post hoc* tests for multiple comparisons were Tukey's test (II – IV) or Dunnett's test (II, V). For non-parametric analyses, the Kruskal-Wallis test was used to evaluate whether a difference existed between any groups. Non-parametric *post hoc* tests were done using Mann-Whitney U-test, followed by Dunn-Sidak (I) or Bonferroni (III) procedure.

For receptor binding data (VI), nonlinear regression analyses were used. The data were fitted to one-site and two-site models, and the fits were compared by F-test. The analyses were performed with Prism 2.0b for Macintosh (GraphPad Software, San Diego, CA, USA).

RESULTS

PLD IN CHROMAFFIN CELL SIGNALLING

The anti-PLD antibody detected a protein of apparent molecular weight of 105 kDa in the particulate protein fraction of adrenal medullary chromaffin cell homogenates. In the soluble fraction, the antibody detected several proteins, all giving only a weak signal (I).

Upon stimulation by angiotensin II (200 nM), bradykinin (100 nM), or PMA (1 μ M) in the presence of 50 mM *n*-butanol, a significant accumulation of phosphatidylbutanol was detected in 5- and 15-min treatments. When butanol was present for the last 15 min of 1-h drug exposure, only PMA was able to sustain a significant transphosphatidylation activity (I).

To assess whether nicotine increases transphosphatidylation activity, ethanol was used instead of *n*-butanol. Neither 10 μ M nicotine nor cell depolarisation by 56 mM K⁺ had any effect in 10-min exposures. However, 1 μ M PMA greatly increased the accumulation of phosphatidylethanol (II). The stimulant effects on phosphatidylethanol accumulation remained unaffected by replacing [³H]oleate with [³H]myristate in phospholipid labelling.

If PLD and phosphatidic acid are crucial in catecholamine exocytosis, primary alcohols should efficiently inhibit secretion. However, ethanol only weakly inhibited nicotine- and KCl-evoked exocytosis, and no selectivity of the primary alcohols over *sec*- and *tert*-butanol, regarded as poor PLD substrates, in inhibition of catecholamine exocytosis was detected. Interestingly, *n*-butanol somewhat increased noradrenaline exocytosis in the absence of other stimulants (II).

Since the inhibitory effect of alcohols on catecholamine release appeared not to be secondary to trapping phosphatidic acid, I recorded their effect on chromaffin cell [Ca⁺⁺]_i. All the alcohols raised [Ca⁺⁺]_i, even in the absence of extracellular Ca⁺⁺. They also inhibited a secretagogue-evoked further increase in [Ca⁺⁺]_i (Table 4; II). An increased fluorescence upon excitation with 340 nm light was always accompanied with a decreased fluorescence upon excitation with 380 nm light.

TABLE 4. Effect of 260 mM ethanol and 160 mM butyl alcohols on [Ca⁺⁺]_i in chromaffin cells in buffer containing either 1 mM CaCl₂ or no Ca⁺⁺ but 100 μ M EGTA, and on the increase in [Ca⁺⁺]_i evoked by sequentially added 10 μ M nicotine and 56 mM KCl, or addition of 1 mM CaCl₂.

	1 mM CaCl ₂			Ca ⁺⁺ -free	
	Alcohol	Nicotine	KCl	Alcohol	1 mM CaCl ₂
control	-1.2 \pm 1.0	380 \pm 40	530 \pm 42	-1.3 \pm 0.60	120 \pm 13
ethanol	63 \pm 11*	290 \pm 29*	420 \pm 33**	23 \pm 2.9	140 \pm 16
<i>n</i> -butanol	380 \pm 26**	-2.3 \pm 1.3**	7.6 \pm 5.6**	130 \pm 14**	270 \pm 32**
<i>sec</i> -butanol	230 \pm 18**	12 \pm 11**	100 \pm 5.8**	120 \pm 7.5**	180 \pm 11*
<i>tert</i> -butanol	200 \pm 18**	-3.3 \pm 1.6**	210 \pm 17**	52 \pm 3.3**	180 \pm 17*

Values reflect the change in [Ca⁺⁺]_i in nM (mean \pm standard error). Asterisks indicate statistically significant differences *vs.* corresponding controls by Dunnett's test (*p < 0.05, **p < 0.01).

The alcohol-evoked apparent increase in [Ca⁺⁺]_i could be due to cytotoxicity. However, a 2-h exposure to the alcohols at the concentrations used in the noradrenaline release and [Ca⁺⁺]_i experiments was not cytotoxic to chromaffin cells, as estimated by reduction of MTT (II).

COTININE EFFECTS ON CHROMAFFIN CELLS

In agreement with previous knowledge (Tuominen *et al.*, 1992), nicotine was observed to increase specific [³H]phorbol dibutyrate binding, reflecting PKC activity, to chromaffin cells upon both 15-min and 24-h exposures. Cotinine alone also increased [³H]phorbol dibutyrate binding upon 15-min but not 24-h exposure. Nonetheless, cotinine pretreatment for 10 min, at 1 mM and higher concentrations, and for 24 h, at 100 μM – 10 mM, resulted in a decrease in the nicotine-induced binding (III).

The altered [³H]phorbol dibutyrate binding suggested redistribution of PKC. In enzyme assays, a 24-h incubation of the cells with 1 mM cotinine failed to increase the PKC kinetic activity in the particulate protein fraction. However, the nicotine-induced increase in membrane-bound PKC activity was markedly decreased by the same treatment (III). Cytotoxicity of cotinine could in part explain its inhibitory effect on nicotine-induced PKC activity. Nevertheless, significant inhibition in the MTT reduction was detected only at higher concentrations than those used in the PKC and phorbol-binding assays (III).

When the chromaffin cells were incubated in the absence of stimulants after a 60-min labelling period with [³H]noradrenaline, the basal [³H]noradrenaline release over a 20-min period was 7 – 8% of the cellular contents (III). Nicotine and DMPP, for the latter 10 min, dose-dependently increased the release as anticipated. A 10-min pre-incubation with 10 mM cotinine increased basal release slightly but significantly (III). To reduce non-specific noradrenaline release, 2 mg ml⁻¹ bovine serum albumin was added to the incubation buffer. In addition, the labelling time with [³H]noradrenaline was reduced to 10 min. These measures drastically reduced basal label release during incubations of 10 s – 20 min. Under these circumstances, cotinine concentration- and time-dependently stimulated [³H]noradrenaline exocytosis (Table 5; IV).

TABLE 5. Time-dependence of cotinine-evoked [³H]noradrenaline release as percentage of cellular label.

	10 s	60 s	10 min	20 min
control	0.35 ± 0.055	1.1 ± 0.092	1.4 ± 0.080	1.9 ± 0.32
peak effect (at [cotinine])	1.4 ± 0.13 (32 mM)	5.9 ± 0.17 (10 mM)	28 ± 0.27 (3.2 mM)	31 ± 0.98 (3.2 mM)
effect of 10 μM nicotine	0.58 ± 0.070	5.0 ± 0.21	33 ± 0.21	37 ± 0.87

Cotinine clearly and significantly inhibited the release caused by nicotine and DMPP. The effect of cotinine on nicotine-evoked release was dose-dependent. However, cotinine did not appear to be a general membrane-stabilising agent, as the exocytotic effects of high extracellular K⁺ (56 mM) and veratrine (10 mg l⁻¹) were not reduced. Indeed, cotinine slightly but significantly increased the veratrine-induced release (III).

Cotinine, at concentrations of 10 – 32 mM, also significantly increased the binding of [³H]phorbol dibutyrate to chromaffin cells in 15-min but not in 24-h incubations. This effect was inhibited by the nicotinic receptor channel blocker hexamethonium. In line with this, a 30-min exposure to 10 mM cotinine increased the membrane-associated PKC activity (IV). The PKC isoenzymes activated by cotinine appeared to be cPKCα and nPKCε, as indicated by Western blot. The cPKCβ1 and cPKCβ2 were not translocated, while the anti-rat PKC antibodies against γ, δ and ζ isoenzymes recognised no protein in the bovine chromaffin cell electrophoresis preparations (IV).

The cotinine-evoked effects on noradrenaline release could well be mediated by nicotinic acetylcholine receptor activation and increased [Ca⁺⁺]_i. Indeed, cotinine, at concentrations of 320 μM and higher, increased the [Ca⁺⁺]_i. The effect of cotinine on [Ca⁺⁺]_i

was inhibited by both competitive and non-competitive nicotinic receptor antagonists, as well as by omitting extracellular Ca^{++} (V). Inhibition occurred, in part, by blocking the voltage-dependent L-type calcium channels by 300 nM nimodipine. Emptying the endoplasmic reticular Ca^{++} stores with 1 μM thapsigargin, a Ca^{++} -ATPase inhibitor, increased the chromaffin cell $[\text{Ca}^{++}]_i$ but had no effect on the response to cotinine. Nor did the blockade of voltage-sensitive sodium channels with 10 μM tetrodotoxin affect the cotinine-induced increase in $[\text{Ca}^{++}]_i$ (V).

In addition to its own effect, cotinine dose-dependently inhibited the nicotine-induced rise in $[\text{Ca}^{++}]_i$. Reciprocally, nicotine pretreatment inhibited the cotinine-induced rise in $[\text{Ca}^{++}]_i$. Cotinine also inhibited the effect of administration of additional cotinine (V).

COTININE BINDING TO NICOTINIC ACETYLCHOLINE RECEPTORS

Finally, a nicotinic receptor binding assay for bovine chromaffin cell membrane homogenates was established. The radioligand, $[\text{}^3\text{H}]$ epibatidine, bound to membranes in a saturable fashion. Upon analysis, the Rosenthal plots appeared curvilinear, and a non-linear regression analysis revealed a significantly better fit for two-site than for one-site binding. The apparent K_d values were 93 pM and 1 400 pM, with B_{max} values of 98 fmol mg^{-1} and 220 fmol mg^{-1} , respectively (VI).

Cotinine, as well as the competitive nicotinic receptor ligands nicotine, methyllycaconitine and dihydro- β -erythroidine displaced 100 pM and 1 nM $[\text{}^3\text{H}]$ epibatidine from its chromaffin cell binding sites, fitting to a one-site binding model (VI). Nicotine was the most potent of the competitors tested (concentrations causing half-maximal inhibition 0.30 and 1.6 μM upon labelling with 100 pM and 1 nM $[\text{}^3\text{H}]$ epibatidine, respectively), followed by methyllycaconitine (1.9 and 4.8 μM), dihydro- β -erythroidine (75 and 160 μM) and cotinine (130 and 310 μM). Alpha-bungarotoxin, over a concentration range of 100 pM – 10 μM , was unable to displace 100 pM $[\text{}^3\text{H}]$ epibatidine. However, 10 nM – 10 μM α -bungarotoxin displaced 17 % of the bound radioligand upon labelling with 1 nM $[\text{}^3\text{H}]$ epibatidine.

In rat frontal cortex and hippocampus, the $[\text{}^3\text{H}]$ epibatidine saturation binding was consistent with a one-site model. The affinity was twice that observed for chromaffin cell high-affinity sites. In frontal cortex and hippocampus, nicotine affinity (K_i 8.6 – 13 nM and 12 – 22 nM, respectively) was ten times and cotinine affinity (K_i 2.3 – 3.8 μM and 3.0 – 4.8 μM) even more higher than in the chromaffin cell preparation (VI).

DISCUSSION

METHODOLOGICAL CONSIDERATIONS

To evaluate whether functional PLD activity in bovine chromaffin cells exists, the cells were exposed to primary alcohol together with the stimulants. In such a medium, PLD yields metabolically more stable phosphatidylbutanol instead of phosphatidic acid (Thompson *et al.*, 1991; Singer *et al.*, 1997). The phosphatidylalcohol was allowed to accumulate for 5 – 15 min, which was considered sufficiently long to answer the question of whether PLD activity in chromaffin cells could be stimulated in a receptor-mediated manner or by PMA, a universal activator of PLD1. In the first studies, *n*-butanol was used as the substrate alcohol. Since at the 50 mM concentration used in PLD assay, *n*-butanol inhibits nicotinic responses (Harper and Littleton, 1990) and voltage-activated channels (Elliott and Elliott, 1994), ethanol was used when nicotinic responses were studied.

In noradrenaline secretion experiments, the addition of albumin to the release buffer greatly reduced the basal release, as also previously recorded (Powis and O'Brien, 1991). Furthermore, adequate dose-response curves for cotinine were obtained only in the presence of albumin, while in its absence spontaneous release or overflow may have masked much of the effect, especially at lower concentration.

In histone kinase assay, some of the PKC activity remains undetected because histone is phosphorylated only by the conventional PKC isoenzymes, α , β and γ , requiring both diglycerides and Ca^{++} for their activation (Marais and Parker, 1989; Schaap *et al.*, 1989; Olivier and Parker, 1991; Liyanage *et al.*, 1992). Moreover, since a risk of PKC redistribution and proteolysis exists during sample preparation, methods, such as phorbol binding, avoiding major sample preparation steps are indicated.

[^3H]Phorbol-12,13-dibutyrate binding can be performed utilising intact cells. Therefore, sample preparation, with the associated risks therein, is not needed. In short-term incubations with substimulatory concentrations of the phorbol ester, the binding occurs at membrane-translocated PKC and reflects the *in situ* PKC activity (Trilivas and Brown, 1989; Rasmussen *et al.*, 1992). In primary cultures of bovine adrenal medullary cells, prepared essentially as in the present work, the non-chromaffin cells represent only 7% of the total specific binding (Tuominen *et al.*, 1991). Thus, phorbol binding can be reasoned to be a valid measure of PKC activity in the chromaffin cell model. However, other receptors for phorbol esters also exist (Ron and Kazanietz, 1999).

Although kinase assay using different subcellular extracts is a widely used method for demonstrating PKC translocation, Western blot has been claimed to be the only reliable way to demonstrate PKC translocation (Parker, 1992), and it is the only way of showing the isoenzyme-specific changes. Nevertheless, it is complicated by species-specific differences in protein sequences and immunogenic properties. Bovine-specific antibodies against PKC isoenzymes are not readily available, and the only sequenced bovine isoenzymes are conventional (Bairoch and Apweiler, 1999). In the present work, most of the PKC antibodies raised against rat carboxyterminal sequences (Wetsel *et al.*, 1992) cross-reacted with bovine proteins. However, the anti-EYINPLLLSAEESV antibody failed to recognise the bovine $\alpha\text{PKC}\zeta$, although the isoenzyme has previously been detected in bovine chromaffin cells with an apparent molecular weight of 80 000 (Pavlovic-Surjancev *et al.*, 1993).

PHOSPHOLIPASE D IN CHROMAFFIN CELL NICOTINIC RESPONSES

PLD activity has previously been suggested to be lacking from bovine adrenal chromaffin cells, as no accumulation of [32 P]phosphatidylbutanol was observed in [32 P] $_i$ prelabelled cells treated with 50 mM butanol and either PMA or bradykinin (Purkiss *et al.*, 1991). Contradictory results have also been obtained (García *et al.*, 1992; Caumont *et al.*, 1998), but the existence of PLD in bovine chromaffin cells had yet to be confirmed (Boarder, 1993; García *et al.*, 1993; Glenn *et al.*, 1998). Interestingly, the nicotine-evoked activation of PLD (Caumont *et al.*, 1998) has not been invariably recorded, and nicotine has actually been reported to inhibit PLD activation induced by β amyloid in a neuroblastoma cell line (Singh *et al.*, 1998).

The present study demonstrates the existence of a 105 kDa protein detected by anti-PLD antibody in bovine adrenal chromaffin cells. As sequences similar to the peptide CIIGSANINERS, against which the antibody was raised, are known only in the PLD proteins (Bairoch and Apweiler, 1999), the finding strongly suggests the existence of PLD in the chromaffin cells. Immunoreactivity was detected mainly in the particulate protein fraction. This is in agreement with previous findings that PLD is mainly associated with various membrane structures. However, the subcellular localisation of PLD may vary between cell types (Provost *et al.*, 1996; Brown *et al.*, 1998).

The present results clearly demonstrate that activation of PKC by PMA and receptor-mediated stimulation by Sar¹-angiotensin II and bradykinin increase transphosphatidylation activity in bovine adrenal chromaffin cells, in contrast to results previously obtained with bradykinin and PMA stimulations of [32 P] $_i$ prelabelled cells (Purkiss *et al.*, 1991). Differences in labelling are unlikely, at least alone, to explain the different results. A possible explanation is the difference in the number of cells per sample, which was 15 times higher in the present study. An increased PLD activity was sustained for an hour upon continuous exposure to PMA. However, I was unable to demonstrate a prolonged activation of PLD by Sar¹-angiotensin II or bradykinin. In this sense, the role of PLD in chromaffin cells differs from that in adrenal cortical cells, which sustain PLD activity upon a continuous exposure to angiotensin II (Jung *et al.*, 1998). When phosphatidylethanol formation was measured, nicotine and a depolarising concentration of potassium had no effect on PLD activity, while PMA again strongly stimulated the enzyme. This lies in stark contrast to a previous report despite largely similar methodology (Caumont *et al.*, 1998). The signalling pathway leading to angiotensin- and nicotine-induced prolonged diacylglycerol production and protein kinase C activity in bovine chromaffin cells thus remains to be clarified. The putative PC-PLC may still have a crucial role as previously suggested (Liscovitch, 1992; Nishizuka, 1992).

PLD activation has been hypothesised to play an important role in exocytosis from various cell types, including PC12 pheochromocytoma cells (Kanoh *et al.*, 1992; Cockcroft, 1996). If PLD is crucial for chromaffin cell exocytosis, trapping phosphatidic acid by primary alcohols should inhibit secretion. In my study, this inhibition did occur. However, no selectivity of primary alkanols over *sec*- and *tert*-butanol was detected. This is in line with previous findings on alkanol effects (Harper and Littleton, 1990; Wood *et al.*, 1991; Alifimoff *et al.*, 1993), but largely conflicts with the results and interpretation of Caumont *et al.* (1998).

All the butyl alcohols tested efficiently inhibited induction of further Ca⁺⁺ transients by secretagogues. Ethanol, at the same mass concentration, was less efficient. The

reason for reduced exocytosis by nicotine and K^+ from bovine chromaffin cells thus appears to lie on the cell membrane. The effects of the alkanols on exocytosis, at concentrations adopted from Caumont *et al.* (1998), seemingly are not PLD-dependent. The role of PLD in chromaffin cell exocytosis is further questioned in that highly active bacterial PLD does not reconstitute the Ca^{++} -dependent exocytosis from permeabilised bovine chromaffin cells (Glenn *et al.*, 1998). The different results between the present and the previous studies (Purkiss *et al.*, 1991; Caumont *et al.*, 1998) cannot be fully explained, although differences in the cell preparation and culture conditions cannot be ruled out as a source of variation.

Interestingly, all the alcohols tested raised the $[Ca^{++}]_i$. The effect was reduced but not totally abolished in the absence of extracellular Ca^{++} , suggesting a release from the intracellular stores. Although *n*-butanol increased the $[Ca^{++}]_i$ roughly as much as nicotine, it only weakly stimulated the noradrenaline secretion. A similar phenomenon is known to occur upon exposure to thapsigargin (Xu *et al.*, 1992), suggesting the possibility that the $[Ca^{++}]_i$ response is initiated at the level of endoplasmic reticular Ca^{++} stores, and the secretion remains small despite increased $[Ca^{++}]_i$. However, the possible store-emptying effect of alcohols does not explain the reduced response to nicotine (Mollard *et al.*, 1995).

COTININE PHARMACOLOGY

In the present study, cotinine inhibition of nicotinic responses was detected in several parameters: phorbol-12,13-dibutyrate binding, PKC activity, noradrenaline release and $[Ca^{++}]_i$. As no inhibition of responses evoked by cell depolarisation by veratrine or high K^+ were detected, involvement of nicotinic receptors in the responses seems probable. In addition, cotinine as such evoked responses mimicking those of nicotine: it evoked noradrenaline release, stimulated phorbol-12,13-dibutyrate binding, increased membrane-associated PKC activity and raised $[Ca^{++}]_i$, many of these being reversed by nicotinic antagonists. Furthermore, cotinine inhibited its own effects on $[Ca^{++}]_i$, and its effects were also inhibited by nicotine. The maximum effect of cotinine on noradrenaline release was followed by a reduction in the response, as happens also upon exposure to nicotine (Kilpatrick *et al.*, 1980; Livett *et al.*, 1981). In prolonged incubations, the peak cotinine effect on noradrenaline release was smaller than that observed with 10 μ M nicotine. These results altogether suggest that cotinine is a low-affinity partial nicotinic agonist at chromaffin cell acetylcholine receptors, also capable of desensitising the receptors.

My results on the effects of ion channel blockers on cotinine-evoked Ca^{++} transients are in accord with findings that micromolar tetrodotoxin has only a minor, if any, effect on exocytosis from chromaffin cells stimulated with 10 – 100 μ M acetylcholine (Kilpatrick *et al.*, 1981), and that at submicromolar concentrations, nimodipine reduces $^{45}Ca^{++}$ uptake evoked by nicotinic stimulation into chromaffin cells only in part (Gandia *et al.*, 1991). At micromolar concentrations, nimodipine and various other L-type calcium channel antagonists inhibit nicotinic receptor ion fluxes (Donnelly-Roberts *et al.*, 1995), hence raising nimodipine concentrations from the 300 nM used would have been inadequate. Therefore, I reason that the cotinine-evoked Ca^{++} influx largely occurs through nicotinic cholinergic receptors. The submicromolar increases in $[Ca^{++}]_i$ detected might well be mediated by chromaffin cell nicotinic receptor channels, as previously calculated (Zhou and Neher, 1993).

The binding of cotinine to chromaffin cell nicotinic acetylcholine receptors at concentrations roughly comparable with those needed to evoke responses was also established in the present study. Thus, the questions raised originally and along this work have largely been answered. Nevertheless, the affinity of cotinine to nicotinic acetylcholine receptors in the bovine chromaffin cells was weak, and the low micromolar concentrations reached upon human nicotine administration (Benowitz *et al.*, 1983; Benowitz and Jacob, 1994) are unlikely to stimulate the receptors. The same appears true for frontal cortical and hippocampal nicotinic receptors, although they more avidly bind cotinine. Indeed, the affinity data are in agreement with the observed functional potency difference of cotinine between chromaffin and central neuronal preparations (Dwoskin *et al.*, 1999).

In the present model, cotinine effects are seemingly evoked by activation of the nicotinic acetylcholine receptors. This leads to Ca^{++} influx through the receptors and voltage-operated calcium channels, activation of PKC and noradrenaline release. The PKC isoenzymes activated include cPKC α and nPKC ϵ in chromaffin cells. The PKC activation is probably mediated by Ca^{++} -stimulated PI-PLC, since the nPKC ϵ *per se* is Ca^{++} -independent. Yet, cotinine increased $[\text{Ca}^{++}]_i$ similarly in both thapsigargin-treated and control cells. This suggests that in cotinine-induced chromaffin cell activation, the release of Ca^{++} from endoplasmic reticulum plays only a minor, if any, role. Despite being considered important in the exocytotic process of various cell types (Kanoh *et al.*, 1992; Cockcroft, 1996), PLD does not appear to be involved in the nicotinic or depolarisation-evoked signalling in bovine chromaffin cells, although the converse has also been reported (Caumont *et al.*, 1998).

Bovine chromaffin cells express genes encoding the $\alpha 3$, $\alpha 5$, $\alpha 7$ and $\beta 4$, but not the $\beta 2$, nicotinic acetylcholine receptor subunits (Campos-Caro *et al.*, 1997; Wenger *et al.*, 1997). Thus, $\alpha 3\beta 4^*$ heteromers, containing or lacking the $\alpha 5$ subunit, and $\alpha 7$ homomers are the possible pentameric subunit combinations. The human $\alpha 7$ homomers are only weakly activated but readily inhibited by cotinine (Briggs and McKenna, 1998), and their activation by nicotine requires high micromolar concentrations (Briggs *et al.*, 1999). When my findings on cotinine effects on noradrenaline release and Ca^{++} transients are reflected against the existing data on mammalian $\alpha 7$ receptors, these do not appear the probable target of cotinine in bovine adrenal chromaffin cells.

My results demonstrating two agonist affinity classes of receptors on bovine adrenal chromaffin cells are different from a report based on ^3H nicotine as the label (Lee *et al.*, 1992). The different affinities may reflect different receptor compositions or they may indicate the presence of receptors with different affinity states. The 15-fold difference between the high- and low-affinity sites observed in the present work agrees with the 15- to 50-fold difference observed in $\alpha 3^*$ receptors of human neuroblastoma SH-SY5Y cells (Wang *et al.*, 1996; Peng *et al.*, 1997). However, the cell line also expresses $\beta 2$ subunits, foreign to bovine chromaffin cells. Furthermore, the affinity I obtained for dihydro- β -erythroidine is similar to that reported for rat $\alpha 3\beta 4$ receptors (Xiao *et al.*, 1998). Another possibility is that the low-affinity receptor class represents the $\alpha 7$ homomeric receptors, which are less sensitive to epibatidine than the heteropentameric neuronal nicotinic receptors (Gerzanich *et al.*, 1995; Delbono *et al.*, 1997). However, α -bungarotoxin displaced only one sixth of the label when 1 nM ^3H epibatidine was used, and it was totally ineffective in displacing 100 pM epibatidine. The relatively low affinity of methyllycaconitine to the receptors and the micromolar concentrations required also argue against a major involvement of $\alpha 7$ homomers in

the two-site binding, but fits better to the data previously obtained with $\alpha 3\beta 4$ receptors (López *et al.*, 1998).

In light of the pre-existing data and my results, the apparent two-site binding probably reflects different affinity states of the $\alpha 3\beta 4^*$ receptors. However, the apparent two-site binding is a mathematical model of the results obtained, and the actual binding of the label may be, and probably is, more complicated. Therefore, caution is needed in deducing the real nature of the apparent binding sites. In the brain, the apparent one-site binding most likely occurs at the $\alpha 4\beta 2$ receptors. The cotinine affinity to the brain receptors was over an order of magnitude higher than to the chromaffin cell receptors. The binding of cotinine to brain receptors also explains cotinine effects detected on brain preparations *in vitro* (Dwoskin *et al.*, 1999).

Most likely, activation is not the primary means of cotinine affecting cholinergic receptors *in vivo*. This is supported by the present results that relatively low cotinine concentrations inhibit nicotinic responses, while high concentrations are required for receptor activation. In fact, most nicotinic agonists desensitise their receptors at lower concentrations than are required for activation (Marks *et al.*, 1996). As the desensitisation is well established in both repeated and continuous exposure of cells to nicotinic agonists (Boksa and Livett, 1984; Marley, 1988), it may apply to cotinine as well. Data suggesting such a phenomenon in oocyte-expressed human $\alpha 7$ receptors has been presented (Briggs and McKenna, 1998). By silencing nicotinic receptors, cotinine may counteract some of the effects of nicotinic agonists at the concentrations reached with tobacco or alternative nicotine use, even without detectable stimulation. The phenomenon may have a role in the clinical effects of cotinine, such as a worsening of tobacco withdrawal symptoms (Keenan *et al.*, 1994; Hatsukami *et al.*, 1998). However, the effects of smoking and nicotine replacement therapy may well be secondary to receptor desensitisation. This is even likely since the concentrations of nicotine reached upon voluntary administration (Benowitz *et al.*, 1988; Gourlay and Benowitz, 1997) are insufficient to activate nicotinic acetylcholine receptors, but rather desensitise them (Marks *et al.*, 1996).

CONCLUSIONS

- 1 Bovine adrenal chromaffin cells possess PLD protein and PLD1-like activity that can be activated by G-protein coupled receptor activators angiotensin II and bradykinin, and by phorbol ester stimulation of PKC.
- 2 PLD activation is not necessary for chromaffin cell exocytosis. Neither does PLD participate in nicotine signalling nor in sustained chromaffin cell responses to angiotensin II or bradykinin.
- 3 Cotinine inhibits nicotinic responses, such as elevation of $[Ca^{++}]_i$, increase in PKC activity and noradrenaline exocytosis, in bovine adrenal chromaffin cells.
- 4 Cotinine efficiently stimulates bovine adrenal chromaffin cells, but high concentrations are required. The cotinine-evoked responses include elevation of $[Ca^{++}]_i$, increase in PKC activity, and noradrenaline exocytosis.
- 5 Cotinine binds to nicotinic binding sites at acetylcholine receptors. The nicotinic acetylcholine receptor agonism initiates the chromaffin cell responses to cotinine.
- 6 Cotinine affinity for nicotinic acetylcholine receptors is low, and the cotinine concentrations achieved in nicotine consumption are likely to affect the receptor activity states.

ACKNOWLEDGEMENTS

This work was made at the Department of Pharmacology and Toxicology of the Institute of Biomedicine and hence made possible by Professor Heikki Vapaatalo, the Head of the Department of Pharmacology and Toxicology, Professor Ismo Virtanen, the Head of the Institute of Biomedicine, and Professor Olli A. Jänne, the former Head of the Institute of Biomedicine.

Professor Raimo K. Tuominen kindly welcomed me to his signal transduction group, provided me the topic of this series of studies and helped me to navigate in the jungle of signalling molecules. I am grateful for the time and effort he invested into my progress.

I wish to thank my senior coworkers Dr. Matti Viluksela, Professor Kid Törnquist, and Dr. Pentti Somerharju for helping me to approach various questions in toxicology and calcium and lipid signalling.

I express my gratitude to my peers Dr. Tiina Jaakkola, Dr. Charlotta Sandler, Dr. Paula Savolainen, Dr. Ilkka Reenilä, and Dr. Martti Törnwall. Ms. Vuokko Pahlsten has been for technical help in various phases of this study and Mr. Esa Oja has successfully hunted for literature whenever needed.

Professors Mauri J. Mattila, Matti K. Paasonen and Pekka Rauhala have expressed interest towards my work, provided valuable hints, and asked critical questions stimulating my growth as a pharmacologist.

Dr. Hannu Komulainen and Dr. Hannu Kankaanranta reviewed the manuscript of this thesis and provided constructive criticism and comments.

I really have enjoyed the co-operation and the more or less scientific discussions with Dr. Michael K. McMillian, Dr. Jyrki Vanakoski, Dr. Kari Eklund, and Dr. Elina Ekokoski.

Finally, I express my deep gratitude to my dear wife Minna; for support, criticism and love.

I am grateful to the sources of funding: Yrjö Jahnsson foundation, the Academy of Finland, University of Helsinki Chancellor, the Research and Science Foundation of Farmos, Duodecim, Magnus Ehrnrooth Foundation and Finnish Pharmacological Society.

Thank you, all!

Petri Vainio

REFERENCES

- Aboud LG, Grassi S, Costanza M. 1983. Binding of optically pure (-)-[³H]nicotine to rat brain membranes. *FEBS Lett* 157: 147-149.
- Aboud LG, Grassi S, Junig J, Crane A, Costanzo M. 1985. Specific binding and metabolism of (-)- and (+)-[³H]-nicotine in isolated rat hepatocytes and hepatocyte membranes. *Arch Int Pharmacodyn* 273: 62-73.
- Adams ME, Swanson G (ed). 1996. *TINS Neurotoxins Supplement*, 2nd edn. Elsevier, Cambridge.
- Aderem A, Seyrkora JT. 1992. The MARCKS protein: a PKC substrate which regulates cytoskeletal-membrane interactions. In: Lester DS, Eband RM (eds) *Protein kinase C, current concepts and future perspectives*. Ellis Horwood, New York, pp 255-273.
- Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD (ed). 1994. *Molecular Biology of the Cell*, 3rd edn. Garland Publishing, New York.
- Alexander S, Peters J (ed). 1999. *TiPS Receptor and Ion Channel Nomenclature Supplement*, 10th edn. Elsevier, Cambridge.
- Alifimoff JK, Bugge B, Forman SA, Miller KW. 1993. Stereoselectivity of channel inhibition by secondary alkanol enantiomers at nicotinic acetylcholine receptors. *Anesthesiology* 79: 122-128.
- Alkondon M, Pereira EFR, Eisenberg HM, Albuquerque EX. 2000. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. *J Neurosci* 20: 66-75.
- Andersson K, Jansson A, Kuylenstierna F, Eneroth P. 1993. Nicotine and its major metabolite cotinine have different effects on aldosterone and prolactin serum levels in the normal male rat. *Eur J Pharmacol* 228: 305-312.
- Anonymous. 1991. Nicotine. In: Dollery C (ed.) *Therapeutic Drugs*. Churchill Livingstone, Edinburgh, pp N65-N72.
- Armitage AK, Turner DM. 1970. Absorption of nicotine in cigarette and cigar smoke through the oral mucosa. *Nature* 226: 1231-1232.
- Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkievicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS, Wasizak JT, M W. 1994. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. *In vitro* characterization. *J Pharmacol Exp Ther* 270: 310-318.
- Auerbach A, Akk G. 1998. Desensitization of mouse nicotinic acetylcholine receptor channels. *J Gen Phys* 112: 181-197.
- Badio B, Daly JW. 1994. Epibatidine, a potent analgetic and nicotinic agonist. *Mol Pharmacol* 45: 563-569.
- Bairoch A, Apweiler R. 1999. The SWISS-PROT protein sequence data bank and its supplement TrEMBL in 1999. *Nucleic Acids Res* 27: 49-54.
- Ballesta JJ, Borges R, Garcia AG, Hidalgo MJ. 1989. Secretory and radioligand binding studies on muscarinic receptors in bovine and feline chromaffin cells. *J Physiol* 418: 411-426.
- Bencherif M, Lovette ME, Fowler KW, Arrington S, Reeves L, Caldwell WS, Lippiello PM. 1996. RJR-2403: a nicotinic agonist with CNS selectivity I. *In vitro* characterization. *J Pharmacol Exp Ther* 279: 1413-1421.
- Benowitz NL. 1996. Pharmacology of nicotine: addiction and therapeutics. *Annu Rev Pharmacol Toxicol* 36: 597-613.
- Benowitz NL, Jacob PIII. 1984. Daily intake of nicotine during cigarette smoking. *Clin Pharmacol Ther* 35: 499-504.
- Benowitz NL, Jacob PIII. 1994. Metabolism of nicotine to cotinine studied by a dual stable isotope method. *Clin Pharmacol Ther* 56: 483-493.
- Benowitz NL, Jacob PIII. 1999. Pharmacokinetics and metabolism of nicotine and related alkaloids. In: Arneric SP, Brioni JD (eds) *Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities*. Wiley-Liss, New York, pp 213-234.
- Benowitz NL, Jacob PIII, Fong I, Gupta S. 1994. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. *J Pharmacol Exp Ther* 268: 296-303.
- Benowitz NL, Kuyt F, Jacob PIII, Jones RT, Osman A-L. 1983. Cotinine disposition and effects. *Clin Pharmacol Ther* 34: 604-611.
- Benowitz NL, Porchet H, Sheiner L, Jacob PIII. 1988. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. *Clin Pharmacol Ther* 44: 23-28.
- Berridge MJ. 1993. Inositol trisphosphate and calcium signalling. *Nature* 361: 315-325.
- Berridge MJ. 1998. Neuronal calcium signaling. *Neuron* 21: 13-26.
- Berridge MJ, Bootman MD, Lipp P. 1998. Calcium - a life and death signal. *Nature* 395: 645-648.
- Birmingham AT, Wilson AB. 1965. An analysis of the blocking action of dimethylphenylpiperazinium iodide on the inhibition of isolated small intestine produced by stimulation of the sympathetic nerves. *Br J Pharmacol* 24: 375-386.
- Bligh EG, Dyer WJ. 1959. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol* 37: 911-917.
- Boarder M. 1994. A role for phospholipase D in control of mitogenesis. *Trends Pharmacol Sci* 15: 57-62.

- Boarder MR. 1993. Phospholipase D in chromaffin cells? *J Neurochem* 60: 1978-1979.
- Boksa P, Livett BG. 1984. Desensitization to nicotinic cholinergic agonists and K^+ , agents that stimulate catecholamine secretion, in isolated adrenal chromaffin cells. *J Neurochem* 42: 607-617.
- Borner C, Fabbro D. 1992. PKC and cellular transformation. In: Lester DS, Epand RM (eds) *Protein kinase C, current concepts and future perspectives*. Ellis Horwood, New York, pp 297-354.
- Borzelleca JF, Bowman ER, McKennis H, Jr. 1962. Studies on the respiratory and cardiovascular effects of (-)-cotinine. *J Pharmacol Exp Ther* 137: 313-318.
- Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72: 248-254.
- Briggs CA, McKenna DG. 1998. Activation and inhibition of the human $\alpha 7$ nicotinic acetylcholine receptor by agonists. *Neuropharmacology* 37: 1095-1102.
- Briggs CA, McKenna DG, Monteggia LM, Touma E, Roch J-M, Arneric SP, Gopalakrishnan M, Sullivan JP. 1999. Gain of function mutation of the $\alpha 7$ nicotinic receptor: pharmacology of the human $\alpha 7V274T$ variant. *Eur J Pharmacol* 366: 301-308.
- Brown FD, Thompson N, Saqib KM, Clark JM, Powner D, Thompson NT, Solari R, Wakelam MJO. 1998. Phospholipase D1 localises to secretory granules and lysosomes and is plasma-membrane translocated on cellular stimulation. *Curr Biol* 8: 835-838.
- Budavari S, O'Neil MJ, Smith A, Heckelman PE, Kinneary JF (ed). 1996. *The Merck Index*, 12th edn. Merck & Co, Whitehouse Station, NJ, USA.
- Burns DJ, Bell RM. 1992. Lipid regulation of protein kinase C. In: Lester DS, Epand RM (eds) *Protein kinase C: current concepts and future perspectives*. Ellis Horwood, New York, pp 25-40.
- Byrd GD, Chang K-M, Greene JM, deBethizy JD. 1992. Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3'-hydroxycotinine in smokers. *Drug Metab Dispos* 20: 192-197.
- Campos-Caro A, Smillie FI, Domínguez del Toro E, Rovira JC, Vicente-Agulló F, Chapuli J, Juárez JM, Sala S, Sala F, Ballesta JJ, Criado M. 1997. Neuronal nicotinic acetylcholine receptors on bovine chromaffin cells: cloning, expression, and genomic organization of receptor subunits. *J Neurochem* 68: 488-497.
- Cartier GE, Yoshikami D, Gray WR, Luo S, Olivera BM, McIntosh JM. 1996. A new α -conotoxin which targets $\alpha 3\beta 2$ nicotinic acetylcholine receptors. *J Biol Chem* 271: 7522-7528.
- Caumont A-S, Galas M-C, Vitale N, Aunis D, Bader M-F. 1998. Regulated exocytosis in chromaffin cells: translocation of Arf6 stimulates a plasma membrane-associated phospholipase D. *J Biol Chem* 273: 1373-1379.
- Chahine R, Calderone A, Navarro-Delmas C. 1990. The in vitro effects of nicotine and cotinine on prostacyclin and thromboxane biosynthesis. *Prostaglandins Leukot Essent Fatty Acids* 40: 261-266.
- Cheek TR, O'Sullivan AJ, Moreton RB, Berridge MJ, Burgoyne RD. 1989. Spatial localization of the stimulus-induced rise in cytosolic Ca^{2+} in bovine adrenal chromaffin cells. Distinct nicotinic and muscarinic patterns. *FEBS Lett* 247: 429-434.
- Claudio T, Ballivet M, Patrick J, Heinemann S. 1983. Nucleotide and deduced amino acid sequences of *Torpedo californica* acetylcholine receptor γ -subunit. *Proc Natl Acad Sci (USA)* 80: 1111-1115.
- Cockcroft S. 1996. ARF-regulated phospholipase D: a potential role in membrane traffic. *Chem Phys Lipids* 80: 59-80.
- Colley WC, Sung T-C, Roll R, Jenco J, Hammond SM, Altshuler Y, Bar-Sagi D, Morris AJ, Frohman MA. 1997. Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. *Curr Biol* 7: 191-201.
- Comfurius P, Bevers EM, Zwaal FA. 1990. Enzymatic synthesis of phosphatidylserine on small scale by use of one-phase system. *J Lipid Res* 31: 1719-1721.
- Cook SJ, Wakelam JO. 1992. Epidermal growth factor increases *sn*-1,2-diacylglycerol levels and activates phospholipase D-catalysed phosphatidylcholine breakdown in Swiss 3T3 cells in the absence of inositol-lipid hydrolysis. *Biochem J* 285: 247-253.
- Cosford ND, Bleicher L, Herbaut A, McCallum JS, Vernier JM, Dawson H, Whitten JP, Adams P, Chavez-Noriega L, Correa LD, Crona JH, Mahaffy LS, Menzaghi F, Rao TS, Reid R, Sacaan AI, Santori E, Stauderman KA, Whelan K, Lloyd GK, McDonald IA. 1996. (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. *J Med Chem* 39: 3235-3237.
- Coussens L, Parker PJ, Rhee L, Yang-Feng TL, Chen E, Waterfield MD, Francke U, Ullrich A. 1986. Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. *Science* 233: 859-866.
- Criado M, Alamo L, Navarro A. 1992. Primary structure of an agonist binding subunit of the nicotinic acetylcholine receptor from bovine adrenal chromaffin cells. *Neurochem Res* 17: 281-287.
- Crisp SJ, Dunn MJ. 1994. Detection of proteins on protein blots using chemiluminescent systems. In: Walker JM (ed.) *Basic Protein and Peptide Protocols*. Humana Press, Totowa, pp 233-237.
- Crooks PA, Li M, Dwoskin LP. 1997. Metabolites of nicotine in rat brain after peripheral nicotine

- administration. Cotinine, nornicotine, and norcotinine. *Drug Metab Dispos* 25: 47-54.
- Curvall M, Elwin C, Kazemi-Vala E, Warholm C, Enzell C. 1990. The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. *Eur J Clin Pharmacol* 38: 281-287.
- Damaj MI, Patrick GS, Creasy KR, Martin BR. 1997. Pharmacology of lobeline, a nicotinic receptor ligand. *J Pharmacol Exp Ther* 282: 410-419.
- Dar MS, Bowman ER, Li C. 1994. Intracerebellar nicotinic-cholinergic participation in the cerebellar adenosine modulation of ethanol-induced motor incoordination in mice. *Brain Res* 644: 117-127.
- de Fiebre CM, Meyer EM, Henry JC, Muraskin SI, Kem WR, Papke RL. 1995. Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidene derivative is a selective agonist at neuronal nicotinic α_7 / 125 I- α -bungarotoxin receptor subtypes. *Mol Pharmacol* 47: 164-171.
- Decker MW, Arneric SP. 1999. Nicotinic acetylcholine receptor-targeted compounds: a summary of the development pipeline and therapeutic potential. In: Arneric SP, Brioni JD (eds) *Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities*. Wiley-Liss, New York, pp 395-411.
- Delbono O, Gopalakrishnan M, Renganathan M, Monteggia LM, Messi ML, Sullivan JP. 1997. Activation of the recombinant human α_7 nicotinic acetylcholine receptor significantly raises intracellular free calcium. *J Pharmacol Exp Ther* 280: 428-438.
- Deneris ES, Connolly J, Rogers SW, Duvoisin R. 1991. Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. *Trends Pharmacol Sci* 12: 34-40.
- Donnelly-Roberts DL, Arneric SP, Sullivan JP. 1995. Functional modulation of human "ganglionic-like" neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists. *Biochem Biophys Res Commun* 213: 657-662.
- Donnelly-Roberts DL, Brioni JD. 1999. Preclinical evidence on the neuroprotective effects of nicotinic ligands. In: Arneric SP, Brioni JD (eds) *Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities*. Wiley-Liss, New York, pp 337-348.
- Douglas WW, Kanno T, Sampson SR. 1967a. Effects of acetylcholine and other medullary secretagogues and antagonists on the membrane potential of adrenal chromaffin cells: an analysis employing techniques of tissue culture. *J Physiol* 188: 107-120.
- Douglas WW, Kanno T, Sampson SR. 1967b. Influence of the ionic environment on the membrane potential of adrenal chromaffin cells and on the depolarizing effect of acetylcholine. *J Physiol* 191: 107-121.
- Downing JEG, Role LW. 1987. Activators of protein kinase C enhance acetylcholine receptor desensitization in sympathetic ganglion neurons. *Proc Natl Acad Sci (USA)* 84: 7739-7743.
- Durrant I. 1990. Light-based detection of biomolecules. *Nature* 346: 297-298.
- Dwoskin LP, Teng L, Buxton ST, Crooks PA. 1999. S-(-)-cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3 H]dopamine release from rat striatal slices in a calcium-dependent manner. *J Pharmacol Exp Ther* 288: 905-911.
- Eberhard DA, Cooper CL, Low MG, Holz RW. 1990. Evidence that the inositol phospholipids are necessary for exocytosis. *Biochem J* 268: 15-25.
- Eberhard DA, Holz RW. 1987. Cholinergic stimulation of inositol phosphate formation in bovine adrenal chromaffin cells: distinct nicotinic and muscarinic mechanisms. *J Neurochem* 49: 1634-1643.
- Eberhard DA, Holz RW. 1991. Regulation of the formation of inositol phosphates by calcium, guanine nucleotides and ATP in digitonin-permeabilized bovine adrenal chromaffin cells. *Biochem J* 279: 447-453.
- Eibl H, Kovatchev S. 1981. Preparation of phospholipids and their analogs by phospholipase D. *Methods Enzymol* 72: 632-639.
- El-Bizri H, Clarke PBS. 1994. Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine administered *in vivo*. *Br J Pharmacol* 111: 414-418.
- Elgoyhen AB, Johnson DS, Boulter J, Vetter DE, Heinemann S. 1994. α_9 : An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. *Cell* 79: 705-715.
- Elliott JR, Elliott AA. 1994. The effects of alcohols and other surface-active compounds on neuronal sodium channels. *Prog Neurobiol* 42: 611-683.
- Eneroth P, Fuxe K, Gustafsson J-Å, Hökfelt T, Löfström A, Skett P, Agnati L. 1977. The effect of nicotine on central catecholamine neurons and gonadotropin secretion. III. Studies on prepubertal female rats treated with pregnant mare serum gonadotropin. *Med Biol* 55: 167-176.
- English D, Cui Y, Siddiqui RA. 1996. Messenger functions of phosphatidic acid. *Chem Phys Lipids* 80: 117-132.
- Erenmemisoglu A, Tekol Y. 1994. Do nicotine metabolites have an effect on pain perception? Antinociceptive effect of cotinine in mice. *Pharmazie* 49: 374-375.
- Exton J. 1997. New developments in phospholipase D. *J Biol Chem* 272: 15579-15582.
- Feng J-F, Rhee SG, Im M-J. 1996. Evidence that phospholipase δ 1 is the effector in the G_h (transglutaminase II)-mediated signaling. *J Biol Chem* 271: 16451-16454.

- Fenster CP, Beckmann ML, Parker JC, Sheffield EB, Whitworth TL, Quick MW, Lester RAJ. 1999. Regulation of $\alpha 4\beta 2$ nicotinic receptor desensitization by calcium and protein kinase C. *Mol Pharmacol* 55: 432-443.
- Fletcher GH, Steinbach JH. 1996. Ability of non-depolarizing neuromuscular blocking drugs to act as partial agonists at fetal and adult mouse muscle nicotinic receptors. *Mol Pharmacol* 49: 938-947.
- Flores CM, Hargreaves KM. 1999. Neuronal nicotinic receptors: new targets in the treatment of pain. In: Arneric SP, Brioni JD (eds) *Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities*. Wiley-Liss, New York, pp 359-378.
- Frohman MA, Sung TC, Morris AJ. 1999. Mammalian phospholipase D structure and regulation. *Biochim Biophys Acta* 1439: 175-186.
- Frye RA, Holz RW. 1984. The relationship between arachidonic acid release and catecholamine secretion from cultured bovine adrenal chromaffin cells. *J Neurochem* 43: 146-150.
- Fukami K, Takenawa T. 1989. Quantitative changes in polyphosphoinositides 1,2-diacylglycerol and inositol 1,4,5-trisphosphate by platelet-derived growth factor and prostaglandin $F_{2\alpha}$. *J Biol Chem* 264: 14985-14989.
- Fuxe K, Everitt BJ, Hökfelt T. 1979. On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons. *Pharmacol Biochem Behav* 10: 671-677.
- Gabrielsson J, Bondesson U. 1987. Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat. *J Pharmacokin Biopharmaceut* 15: 583-599.
- Galve-Roperh I, Haro A, Diaz-Laviada I. 1997. Ceramide-induced translocation of protein kinase C ζ in primary cultures of astrocytes. *FEBS Lett* 415: 271-274.
- Gandia L, Casado L-F, López MG, Garcia AG. 1991. Separation of two pathways for calcium entry into chromaffin cells. *Br J Pharmacol* 103: 1073-1078.
- García MC, López MG, García AG, Sánchez Crespo M. 1992. Muscarinic acetylcholine receptor enhances phosphatidylcholine hydrolysis via phospholipase D in bovine chromaffin cells in culture. *J Neurochem* 59: 2244-2250.
- García MC, López MG, García AG, Sánchez Crespo MS. 1993. Reply from M. C. García, M. G. López, A. G. García, and M. Sánchez Crespo. *J Neurochem* 60: 1979-1980.
- García-Colunga J, Miledi R. 1999. Modulation of nicotinic acetylcholine receptors by strychnine. *Proc Natl Acad Sci (USA)* 96: 4113-4118.
- García-Guzmán M, Sala F, Sala S, Campos-Caro A, Stühmer W, Gutiérrez LM, Criado M. 1995. α -Bungarotoxin-sensitive nicotinic receptors on bovine chromaffin cells: molecular cloning, functional expression and alternative splicing of the $\alpha 7$ subunit. *Eur J Neurosci* 7: 647-655.
- Gerzanich V, Peng X, Wang F, Wells G, Anand R, Fletcher S, Lindstrom J. 1995. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. *Mol Pharmacol* 48: 774-782.
- Glenn DE, Thomas GMH, O'Sullivan AJ, Burgoyne RD. 1998. Examination of the role of ADP-ribosylation factor and phospholipase D activation in regulated exocytosis in chromaffin and PC12 cells. *J Neurochem* 71: 2023-2033.
- Gopalakrishnan M, Molinari EJ, Sullivan JP. 1997. Regulation of human $\alpha 4\beta 2$ neuronal nicotinic acetylcholine receptors by cholinergic ligands and second messenger pathways. *Mol Pharmacol* 52: 524-534.
- Gotti C, Fornasari D, Clementi F. 1997. Human neuronal nicotinic receptors. *Prog Neurobiol* 53: 199-237.
- Gourlay SG, Benowitz NL. 1997. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. *Clin Pharmacol Ther* 62: 453-463.
- Griendling KK, Rittenhouse SE, Brock TA, Ekstein LS, Gimbrone MA, Jr, Alexander RW. 1986. Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. *J Biol Chem* 261: 5901-5906.
- Gryniewicz G, Poenie M, Tsien RY. 1985. A new generation of Ca^{2+} indicators with greatly improved fluorescence properties. *J Biol Chem* 260: 3440-3450.
- Gudermann T, Kalkbrenner F, Schultz G. 1996. Diversity and selectivity of receptor-G protein interaction. *Annu Rev Pharmacol Toxicol* 36: 429-459.
- Halldin C, Nägren K, Swahn C-G, Långström B, Nybäck H. 1992. (S)- and (R)- $[^{11}C]$ nicotine and the metabolite (R/S)- $[^{11}C]$ cotinine. Preparation, metabolite studies and in vivo distribution in the human brain using PET. *Nucl Med Biol* 19: 871-880.
- Hammond SM, Altshuler YM, Sung T-C, Rudge SA, Rose K, Engebrecht J, Morris AJ, Frohman MA. 1995. Human ADP-ribosylation factor-activated phosphatidylcholine-specific phospholipase D defines a new and highly conserved gene family. *J Biol Chem* 270: 29640-29643.
- Hammond SM, Jenco JM, Nakashima S, Cadwallader K, Gu Q, Cook S, Nozawa Y, Prestwich GD, Frohman MA, Morris AJ. 1997. Characterization of two alternatively spliced forms of phospholipase D1. *J Biol Chem* 272: 3860-3868.
- Hansson E, Schmitterlöw CG. 1965. Metabolism of nicotine in various tissues. In: von Euler US

- (ed.) Tobacco Alkaloids and Related Compounds. Pergamon Press, Oxford, pp 87-97.
- Harper JC, Littleton JM. 1990. Development of tolerance to ethanol in cultured adrenal chromaffin cells. *Alcohol Clin Exp Res* 14: 508-512.
- Hatsukami D, Pentel PR, Jensen J, Nelson D, Allen SS, Goldman A, Rafael D. 1998. Cotinine: effects with and without nicotine. *Psychopharmacology* 135: 141-150.
- Haylett DG. 1996. Direct measurement of drug binding to receptors. In: Foreman JC, Johansen T (eds) *Textbook of Receptor Pharmacology*. CRC Press, Boca Raton, pp 121-149.
- Hepler JR, Kozasa T, Smrcka AV, I SM, Rhee SG, Sternweis PC, Gilman AG. 1993. Purification from Sf9 cells and characterization of recombinant Gq α and G11 α . Activation of purified phospholipase C isozymes by G α subunits. *J Biol Chem* 268: 14367-14375.
- Hoffmann D, Wynder EL. 1986. Chemical constituents and bioactivity of tobacco smoke. In: Zaridze D, Peto R (eds) *Tobacco. A Major International Health Hazard*. International Agency for Research on Cancer, Lyon, pp 145-165.
- Holz RW, Senter RA, Frye RA. 1982. Relationship between Ca²⁺ uptake and catecholamine secretion in primary dissociated cultures of adrenal medulla. *J Neurochem* 39: 635-646.
- Horwitz J. 1991. Bradykinin activates a phospholipase D that hydrolyzes phosphatidylcholine in PC12 cells. *J Neurochem* 56: 509-517.
- Horwitz J, Ricanati S. 1992. Bradykinin and phorbol dibutyrate activate phospholipase D in PC12 cell by different mechanisms. *J Neurochem* 59: 1474-1480.
- Houle MG, Bourgoin S. 1999. Regulation of phospholipase D by phosphorylation-dependent mechanisms. *Biochim Biophys Acta* 1439: 135-149.
- Huganir RL, Greengard P. 1990. Regulation of neurotransmitter receptor desensitization by protein phosphorylation. *Neuron* 5: 555-567.
- Hurt RD, Dale LC, Offord KP, Lauger GG, Baskin LB, Lawson GM, Jiang NS, Hauri PJ. 1993. Serum nicotine and cotinine levels during nicotine-patch therapy. *Clin Pharmacol Ther* 54: 98-106.
- Hurt RD, Offord KP, Croghan IT, Croghan GA, Gomez-Dahl LC, Wolter TD, Dale LC, Moyer TP. 1998. Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. *Psychopharmacology* 140: 98-104.
- Inoue M, Kishimoto A, Takai Y, Nishizuka Y. 1977. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. *J Biol Chem* 252: 7610-7616.
- IUPHAR Committee on Receptor Nomenclature and Drug Classification. 1998. *The IUPHAR Compendium of Receptor Characterization and Classification*. IUPHAR Media, London.
- Izquierdo I. 1994. Pharmacological evidence for a role of long-term potentiation in memory. *FASEB J* 8: 1139-1145.
- Jaffe JH. 1990. Drug addiction and drug abuse. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 8th edn. McGraw-Hill, New York, pp 522-573.
- Jaken S. 1992. PKC interactions with intracellular components. In: Lester D, Eband R (eds) *Protein kinase C, current concepts and future perspectives*. Ellis Horwood, New York, pp 237-254.
- Jenkinson DH, Barnard EA, Hoyer D, Humphrey PPA, Leff P, Shankley NP. 1998. Terms and symbols in quantitative pharmacology. In: IUPHAR Committee on Receptor Nomenclature and Drug Classification (ed.) *The IUPHAR Compendium of Receptor Characterization and Classification*. IUPHAR Media, London, pp 6-20.
- Johnson DS, Martinez J, Elgoyhen AB, Heinemann SS, McIntosh JM. 1995. α -Conotoxin Iml exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric $\alpha 7$ and $\alpha 9$ receptors. *Mol Pharmacol* 48: 194-199.
- Jones D, Morgan C, Cockcroft S. 1999. Phospholipase D and membrane traffic. Potential roles in regulated exocytosis, membrane delivery and vesicle budding. *Biochim Biophys Acta* 1439: 229-244.
- Jung E, Betancourt-Calle S, Mann-Blakeney R, Foushee T, Isales CM, Bollag WB. 1998. Sustained phospholipase D activation in response to angiotensin II but not carbachol in bovine adrenal glomerulosa cells. *Biochem J* 330: 445-451.
- Kanoh H, Kanaho Y, Nozawa Y. 1992. Pertussis toxin-insensitive G protein mediates carbachol activation of phospholipase D in rat pheochromocytoma PC12 cells. *J Neurochem* 59: 1786-1794.
- Katayama K, Kodaki T, Nagamachi Y, Yamashita S. 1998. Cloning, differential regulation and tissue distribution of alternatively spliced isoforms of ADP-ribosylation-factor-dependent phospholipase D from rat liver. *Biochem J* 329: 647-652.
- Katz B, Thesleff S. 1957. A study of the "desensitization" produced by acetylcholine at the motor end-plate. *J Physiol* 138: 63-80.
- Keenan RM, Hatsukami DK, Pentel PR, Thompson TN, Grillo MA. 1994. Pharmacodynamic effects of cotinine in abstinent cigarette smokers. *Clin Pharmacol Ther* 55: 581-590.
- Kem WR, Mahnir VM, Papke RL, Lingle CJ. 1997. Anabaseine is a potent agonist on muscle and neuronal α -bungarotoxin-sensitive nicotinic receptors. *J Pharmacol Exp Ther* 283: 979-992.
- Kenigsberg RL, Trifaró JM. 1980. Presence of a high affinity uptake system for catecholamines in cultured bovine adrenal chromaffin cells. *Neuroscience* 5: 1547-1556.

- Keranen LM, Newton AC. 1997. Ca²⁺ differentially regulates conventional protein kinase Cs' membrane interaction and activation. *J Biol Chem* 272: 25959-25967.
- Khiroug L, Sokolova E, Giniatullin R, Afzalov R, Nistri A. 1998. Recovery from desensitization of neuronal nicotinic acetylcholine receptors of rat chromaffin cells is modulated by intracellular calcium through distinct second messengers. *J Neurosci* 18: 2458-2466.
- Kikkawa U, Minakuchi R, Takai Y, Nishizuka Y. 1983. Calcium-activated, phospholipid-dependent protein kinase (protein kinase C) from rat brain. *Methods Enzymol* 99: 288-298.
- Kilpatrick DL, Freeman HL, Carson KA, Kirshner AG, Slepatis R, Kirshner N. 1980. Stability of bovine adrenal medulla cells in culture. *J Neurochem* 35: 679-692.
- Kilpatrick DL, Slepatis R, Kirshner N. 1981. Ion channels and membrane potential in stimulus-secretion coupling in adrenal medulla cells. *J Neurochem* 36: 1245-1255.
- Kim KS, Borzelleca JF, Bowman ER, McKennis H, Jr. 1968. Effects of some nicotine metabolites and related compounds on isolated smooth muscle. *J Pharmacol Exp Ther* 161: 59-69.
- Knox RJ, Kaczmarek LK. 1992. Regulation of neuronal ion channels by protein kinase C. In: Lester DS, Epand RM (eds) *Protein kinase C, current concepts and future perspectives*. Ellis Horwood, New York, pp 274-296.
- Kobayashi M, Kanfer JN. 1987. Phosphatidylethanol formation via transphosphatidylation by rat brain synaptosomal phospholipase D. *J Neurochem* 48: 1597-1603.
- Kodaki T, Yamashita S. 1997. Cloning, expression, and characterization of a novel phospholipase D complementary DNA from rat brain. *J Biol Chem* 272: 11408-11413.
- Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685.
- Langley JN. 1905. On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. *J Physiol* 33: 374-413.
- Lee K, Miwa S, Koshimura K, Ito A. 1992. Characterization of nicotinic acetylcholine receptors on cultured bovine adrenal chromaffin cells using modified L-[³H]nicotine binding assay. *Naunyn-Schmiedeberg's Arch Pharmacol* 345: 363-369.
- Leischow SJ, Cook G. 1999. Nicotine and non-nicotine formulations for smoking cessation. In: Arneric SP, Brioni JD (eds) *Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities*. Wiley-Liss, New York, pp 323-336.
- Leonard S, Adler LE, Olincy A, Breese CR, Gault J, Ross RG, Lee M, Cawtra E, Nagamoto HT, Freedman R. 1999. The role of nicotinic receptors in psychopathology. In: Arneric SP, Brioni JD (eds) *Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities*. Wiley-Liss, New York, pp 307-322.
- Levin ED, Simon BB, Connors CK. 1999. Transdermal nicotine treatment of attention deficit hyperactivity disorder. In: Arneric SP, Brioni JD (eds) *Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities*. Wiley-Liss, New York, pp 349-357.
- Lindstrom J. 1999. Purification and cloning of nicotinic acetylcholine receptors. In: Arneric SP, Brioni JD (eds) *Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities*. Wiley-Liss, New York, pp 3-23.
- Lindstrom J, Anand R, Peng X, Gerzanich V, Wang F, Li Y. 1995. Neuronal nicotinic receptor subtypes. *Ann N Y Acad Sci* 757: 100-116.
- Liscovitch M. 1992. Crosstalk among multiple signal-activated phospholipases. *Trends Biochem Sci* 17: 393-399.
- Liscovitch M, Amsterdam A. 1989. Gonadotropin-releasing hormone activates phospholipase D in ovarian granulosa cells. *J Biol Chem* 264: 11762-11767.
- Livett BG. 1984. Adrenal medullary chromaffin cells in vitro. *Physiol Rev* 64: 1103-1161.
- Livett BG, Dean DM, Whelan LG, Udenfriend S, Rossier J. 1981. Co-release of enkephalin and catecholamines from cultured adrenal chromaffin cells. *Nature* 289: 317-319.
- Liyanage M, Frith D, Livneh E, Stabel S. 1992. Protein kinase C group B members PKC- δ , - ϵ , - ζ and PKC-L(η). Comparison of properties and recombinant proteins in vitro and in vivo. *Biochem J* 283: 781-787.
- Loneragan K, Cheah TB, Bunn SJ, Marley PD. 1996. The role of protein kinase C in nicotinic responses of bovine chromaffin cells. *Eur J Pharmacol* 311: 87-94.
- Lopez I, Arnold RS, Lambeth JD. 1998. Cloning and initial characterization of a human phospholipase D2 (hPLD2). *J Biol Chem* 273: 12846-12852.
- López MG, Montiel C, Herrero CJ, García-Palomero E, Mayorgas I, Hernández-Guijo JM, Villaroya M, Olivares R, Gandía L, McIntosh JM, Olivera BM, García AG. 1998. Unmasking the functions of the chromaffin cell $\alpha 7$ nicotinic receptor by using short pulses of acetylcholine and selective blockers. *Proc Natl Acad Sci (USA)* 95: 14184-14189.
- Luetje CW, Wada K, Rogers S, Abramson SN, Tsuji K, Heinemann S, Patrick J. 1990. Neurotoxins distinguish between different neuronal nicotinic acetylcholine receptor subunit combinations. *J Neurochem* 55: 632-640.
- Lukas RJ, Changeaux J-P, Le Novère N, Albuquerque EX, Balfour DJK, Berg DK, Bertrand D, Chiappinelli VA, Clarke PBS, Collins AC, Dani JA, Grady SR, Kellar KJ, Lindstrom JM, Marks

- MJ, Quik M, Taylor PW, Wonnacott S. 1999. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. *Pharmacol Rev* 51: 397-401.
- Lynn JS, Hughes AD. 2000. Phospholipase C isoforms, cytoskeletal organization, and vascular smooth muscle differentiation. *News Physiol Sci* 15: 41-45.
- Marais RM, Parker PJ. 1989. Purification and characterisation of bovine brain protein kinase C isoforms α , β and γ . *Eur J Biochem* 182: 129-137.
- Marks MJ. 1999. Desensitization and the regulation of neuronal nicotinic receptors. In: Arneric SP, Brioni JD (eds) *Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities*. Wiley-Liss, New York, pp 65-80.
- Marks MJ, Robinson SF, Collins AC. 1996. Nicotinic agonists differ in activation and desensitization of $^{86}\text{Rb}^+$ efflux from mouse thalamic synaptosomes. *J Pharmacol Exp Ther* 277: 1383-1396.
- Marley PD. 1988. Desensitization of the nicotinic secretory response of adrenal chromaffin cells. *Trends Pharmacol Sci* 9: 102-107.
- Martinson E, Trilivas I, Brown JH. 1990. Rapid protein kinase C-dependent activation of phospholipase D leads to delayed 1,2-diglyceride accumulation. *J Biol Chem* 265: 22282-22287.
- Massenburg D, Han J-S, Liyanage M, Patton WA, Rhee SG, Moss J, Vaughan M. 1994. Activation of rat brain phospholipase D by ADP-ribosylation factors 1, 5, and 6: separation of ADP-ribosylation factor-dependent and oleate-dependent enzymes. *Proc Natl Acad Sci (USA)* 91: 11718-11722.
- McGehee DS, Role LW. 1995. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. *Annu Rev Physiol* 57: 521-546.
- McKay DB, Lopez I, Sanchez PA, English JL, Wallace LJ. 1991. Characterization of muscarinic receptors of bovine adrenal chromaffin cells: binding, secretion and anti-microtubule drug effects. *Gen Pharmacol* 22: 1185-1189.
- McKay DB, Schneider AS. 1984. Selective inhibition of cholinergic receptor-mediated ^{45}Ca uptake and catecholamine secretion from adrenal chromaffin cells by taxol and vinblastine. *J Pharmacol Exp Ther* 231: 102-108.
- McMillian MK, Tuominen RK, Hudson PM, Suh HH, Hong JS. 1992. Angiotensin II receptors are coupled to ω -conotoxin-sensitive calcium influx in bovine adrenal medullary chromaffin cells. *J Neurochem* 58: 1285-1291.
- McPhail LC, Waite KA, Regier DS, Nixon JB, Qualliotine-Mann D, Zhang WX, Wallin R, Sergeant S. 1999. A novel protein kinase target for the lipid second messenger phosphatidic acid. *Biochim Biophys Acta* 1439: 277-290.
- Meier KE, Gibbs TC, Knoepp SM, Ella KM. 1999. Expression of phospholipase D isoforms in mammalian cells. *Biochim Biophys Acta* 1439: 199-213.
- Mellor H, Parker PJ. 1998. The extended protein kinase C superfamily. *Biochem J* 332: 281-292.
- Menzaghi F, McClure DE, Lloyd GK. 1999. Subtype-selective nAChR agonists for the treatment of neurological disorders: SIB-1508Y and SIB-1553A. In: Arneric SP, Brioni JD (eds) *Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities*. Wiley-Liss, New York, pp 379-394.
- Meyer EM, Kuryatov A, Gerzanich V, Lindstrom J, Papke RL. 1998. Analysis of 3-(4-hydroxy, 2-methoxybenzylidene)anabaseine selectivity and activity at human and rat $\alpha 7$ nicotinic receptors. *J Pharmacol Exp Ther* 287: 918-925.
- Micheau J, Riedel G. 1999. Protein kinases: which one is the memory molecule? *Cell Mol Life Sci* 55: 534-548.
- Mollard P, Seward EP, Nowycky MC. 1995. Activation of nicotinic receptors triggers exocytosis from bovine chromaffin cells in the absence of membrane depolarization. *Proc Natl Acad Sci (USA)* 92: 3065-3069.
- Moolenaar WH. 1995. Lysophosphatidic acid, a multifunctional phospholipid messenger. *J Biol Chem* 270: 12949-12952.
- Moreyra AE, Lacy CR, Wilson AC, Kumar A, Kostis JB. 1992. Arterial blood nicotine concentration and coronary vasoconstrictive effect of low-nicotine cigarette smoking. *Am Heart J* 124: 392-397.
- Morris AJ, Frohman MA, Engebrecht J. 1997a. Measurement of phospholipase D activity. *Anal Biochem* 252: 1-9.
- Morris AJ, Hammond SM, Colley C, Sung T-C, Jenco JM, Sciorra VA, Rudge SA, Frohman MA. 1997b. Regulation and functions of phospholipase D. *Biochem Soc Trans* 25: 1151-1157.
- Motomura M, Niwa M, Kataoka Y, Ootsuru I, Yoshimura T, Tsujihata M, Nagataki S. 1992. *In vitro* quantitative autoradiography of [^{125}I] α -bungarotoxin binding at the motor end-plates of experimental autoimmune myasthenia gravis. *Neurosci Lett* 143: 139-142.
- Mulligan S, Masterson J, Devane J, Kelly J. 1990. Clinical and pharmacokinetic properties of a transdermal nicotine patch. *Clin Pharmacol Ther* 47: 331-336.
- Nakaki T, Sasakawa N, Yamamoto S, Kato R. 1988. Functional shift from muscarinic to nicotinic cholinergic receptors involved in inositol trisphosphate and cyclic GMP accumulation during the primary culture of adrenal chromaffin cells. *Biochem J* 251: 397-403.
- Nakanishi H, Brewer KA, Exton JH. 1993. Activation of the ζ isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem* 268: 13-16.

- Nassar-Gentina V, Catalan L, Luxoro M. 1997. Nicotinic and muscarinic components in acetylcholine stimulation of porcine adrenal medullary cells. *Mol Cell Biochem* 169: 107-113.
- Nishizuka Y. 1984. The role of protein kinase C in cell surface signal transduction and tumour promotion. *Nature* 308: 693-698.
- Nishizuka Y. 1986. Studies and perspectives of protein kinase C. *Science* 233: 305-312.
- Nishizuka Y. 1992. Intracellular signaling by hydrolysis of phospholipids and activation protein kinase C. *Science* 258: 607-614.
- Nishizuka Y. 1995. Protein kinase C and lipid signaling for sustained cellular responses. *FASEB J* 9: 484-496.
- Noda M, Takahashi H, Tanabe T, Toyosato M, Furutani Y, Hirose T, Asai M, Inayama S, Miyata T, Numa S. 1982. Primary structure of α -subunit precursor of *Torpedo californica* acetylcholine receptor deduced from cDNA sequence. *Nature* 299: 793-797.
- Noda M, Takahashi H, Tanabe T, Toyosato M, Kikyotani S, Furutani Y, Hirose T, Takashima H, Inayama S, Miyata T, Numa S. 1983a. Structural homology of *Torpedo californica* acetylcholine receptor subunits. *Nature* 302: 528-532.
- Noda M, Takahashi H, Tanabe T, Toyosato M, Kikyotani S, Hirose T, Asai M, Takashima H, Inayama S, Miyata T, Numa S. 1983b. Primary structures of β - and γ -subunit precursors of *Torpedo californica* acetylcholine receptor deduced from cDNA sequences. *Nature* 301: 251-255.
- Nofer J-R, Tepel M, Walter M, Seedorf U, Assmann G, Zidek W. 1997. Phosphatidylcholine-specific phospholipase C regulates thapsigargin-induced calcium influx in human lymphocytes. *J Biol Chem* 272: 32861-32868.
- Ohno S, Akita Y, Konno Y, Imajoh S, Suzuki K. 1988. A novel phorbol ester receptor/protein kinase, nPKC, distantly related to the protein kinase C family. *Cell* 53: 731-741.
- Okamura S, Yamashita S. 1994. Purification and characterization of phosphatidylcholine phospholipase D from pig lung. *J Biol Chem* 269: 31207-31213.
- Olivier AR, Parker PJ. 1991. Expression and characterization of protein kinase C- δ . *Eur J Biochem* 200: 805-810.
- Ono Y, Fujii T, Ogita K, Kikkawa U, Igarashi K, Nishizuka Y. 1988. The structure, expression, and properties of additional members of the protein kinase C family. *J Biol Chem* 263: 6927-6932.
- Ono Y, Fujii T, Ogita K, Kikkawa U, Igarashi K, Nishizuka Y. 1989. Protein kinase C ζ subspecies from rat brain: its structure, expression, and properties. *Proc Natl Acad Sci (USA)* 86: 3099-3103.
- Papke RL, Bencherif M, Lippiello P. 1996. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the $\alpha 7$ subtype. *Neurosci Lett* 213: 201-204.
- Parker MJ, Beck A, Luetje CW. 1998. Neuronal nicotinic receptor $\beta 2$ and $\beta 4$ subunits confer large differences in agonist binding affinity. *Mol Pharmacol* 54: 1132-1139.
- Parker PJ. 1992. Protein kinase C - a structurally related family of enzymes. In: Lester DS, Eband RM (eds) *Protein kinase C, current concepts and future perspectives*. Ellis Horwood, New York, pp 3-24.
- Parker PJ, Coussens L, Totty N, Rhee L, Young S, Chen E, Stabel S, Waterfield MD, Ullrich A. 1986. The complete primary structure of protein kinase C - the major phorbol ester receptor. *Science* 233: 853-859.
- Patterson TR, Stringham JD, Meikle AW. 1990. Nicotine and cotinine inhibit steroidogenesis in mouse Leydig cells. *Life Sci* 46: 265-272.
- Paulson GW, Olson BL. 1995. Can smoking be detected from cerebrospinal fluid? *Clin Neuropharmacol* 18: 375-376.
- Pavlovic-Surjancev B, Cahill AL, Perlman RL. 1993. Staurosporine activates a 60,000 Mr protein kinase in bovine chromaffin cells that phosphorylates myelin basic protein in vitro. *J Neurochem* 61: 697-703.
- Peng X, Gerzanich V, Anand R, Wang F, Lindstrom J. 1997. Chronic nicotine treatment up-regulates $\alpha 3$ and $\alpha 7$ acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y. *Mol Pharmacol* 51: 776-784.
- Peng X, Gerzanich V, Anand R, Whiting PJ, Lindstrom J. 1994. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. *Mol Pharmacol* 46: 523-530.
- Pinner A. 1893. Ueber Nicotin. *Arch Pharm* 231: 378-448.
- Portilla D, Mordhorst M, Bertrand W, Morrison AR. 1988. Protein kinase C modulates phospholipase C and increases arachidonic acid release in bradykinin stimulated MDCK cells. *Biochem Biophys Res Commun* 153: 454-462.
- Powis DA, O'Brien KJ. 1991. Angiotensin II increases catecholamine release from bovine adrenal medulla but does not enhance that evoked by K^+ depolarization or by carbachol. *J Neurochem* 57: 1461-1469.
- Provost JJ, Fudge J, Siddiqi AR, Exton JH. 1996. Tissue-specific distribution and subcellular distribution of phospholipase D in rat: evidence for distinct RhoA- and ADP-ribosylation factor (ARF)-regulated isoenzymes. *Biochem J* 319: 285-291.
- Purkiss J, Murrin RA, Owen PJ, Boarder MR. 1991. Lack of phospholipase D activity in chromaffin cells: bradykinin-stimulated phosphatidic acid formation involves phospholipase C in chromaffin cells but phospholipase D in PC12 cells. *J Neurochem* 57: 1084-1087.

- Qian Z, Drewes LR. 1989. Muscarinic acetylcholine receptor regulates phosphatidylcholine phospholipase D in canine brain. *J Biol Chem* 264: 21720-21724.
- Ramirez-Latorre J, Crabtree G, Turner J, Role L. 1999. Molecular composition and biophysical characteristics of nicotinic receptors. In: Arneric SP, Brioni JD (eds) *Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities*. Wiley-Liss, New York, pp 43-64.
- Rang HP, Dale MM, Ritter JM. 1999. *Pharmacology*, 4th edn. Churchill Livingstone, Edinburgh.
- Rasmussen H, Calle R, Ganesan S, Smallwood J, Throckmorton D, Zawalich W. 1992. Protein kinase C: role in sustained cellular responses. In: Lester D, Epand R (eds) *Protein kinase C, current concepts and future perspectives*. Ellis Horwood, New York, pp 183-236.
- Riker WK. 1968. Ganglion cell depolarization and transmission block by ACh: independent events. *J Pharmacol Exp Ther* 159: 345-352.
- Rodriguez-Pena A, Rozengurt E. 1984. Disappearance of Ca²⁺-sensitive, phospholipid-dependent protein kinase activity in phorbol ester-treated 3T3 cells. *Biochem Biophys Res Commun* 120: 1053-1059.
- Ron D, Kazanietz MG. 1999. New insights into the regulation of protein kinase C and novel phorbol ester receptors. *FASEB J* 13: 1658-1676.
- Roskoski RJ. 1983. Assays for protein kinase. *Methods Enzymol* 99: 3-6.
- Saareks V, Riutta A, Mucha I, Alanko J, Vapaatalo H. 1993. Nicotine and cotinine modulate eicosanoid production in human leukocytes and platelet rich plasma. *Eur J Pharmacol* 248: 345-349.
- Sacaan AI, Reid RT, Santori EM, Adams P, Correa LD, Mahaffy LS, Bleicher L, Cosford ND, Stauderman KA, McDonald IA, Rao TS, Lloyd GK. 1997. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist. *J Pharmacol Exp Ther* 280: 373-383.
- Saito M, Kanfer J. 1975. Phosphatidohydrolase activity in a solubilized preparation from rat brain particulate fraction. *Arch Biochem Biophys* 169: 318-323.
- Sanberg PR, Shytle RD, Silver AA. 1998. Treatment of Tourette's syndrome with mecamylamine. *Lancet* 352: 705-706.
- Sargent P. 1993. The diversity of neuronal nicotinic acetylcholine receptors. *Annu Rev Neurosci* 16: 403-443.
- Schaap D, Parker PJ, Bristol A, Kriz R, Knopf J. 1989. Unique substrate specificity and regulatory properties of PKC-ε: a rationale for diversity. *FEBS Lett* 243: 351-357.
- Schneider AS, Herz R, Rosenheck K. 1977. Stimulus-secretion coupling in chromaffin cells isolated from bovine adrenal medulla. *Proc Natl Acad Sci (USA)* 74: 5036-5040.
- Schuh KJ, Schuh LM, Henningfield JE, Stitzer ML. 1997. Nicotine nasal spray and vapor inhaler: abuse liability assessment. *Psychopharmacology* 130: 352-361.
- Shinomura T, Asaoka Y, Oka M, Yoshida K, Nishizuka Y. 1991. Synergistic action of diacylglycerol and unsaturated fatty acid for protein kinase C activation: its possible implications. *Proc Natl Acad Sci (USA)* 88: 5149-5153.
- Singer WD, Brown HA, Jiang X, Sternweis PC. 1996. Regulation of phospholipase D by protein kinase C is synergistic with ADP-ribosylation factor and independent of protein kinase activity. *J Biol Chem* 271: 4504-4510.
- Singer WD, Brown HA, Sternweis PC. 1997. Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and phospholipase D. *Annu Rev Biochem* 66: 475-509.
- Singh IN, Sorrentino G, Sitar DS, Kanfer JN. 1998. (-)Nicotine inhibits the activations of phospholipases A2 and D by amyloid β peptide. *Brain Res* 800: 275-281.
- Singh SS, Chauhan A, Brockerhoff H, Chauhan VP. 1993. Activation of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. *Biochem Biophys Res Commun* 195: 104-112.
- Smrcka AV, Hepler JR, Brown KO, Sternweis PC. 1991. Regulation of polyphosphoinositide-specific phospholipase C activity by purified Gq. *Science* 251: 804-880.
- Stachowiak MK, Hong J-S, Viveros H. 1990. Coordinate and differential regulation of phenylethanolamine-N-methyltransferase, tyrosine hydroxylase and proenkephalin mRNAs by neural and hormonal mechanisms in cultured bovine adrenal medullary cells. *Brain Res* 510: 277-288.
- Standaert ML, Bandyopadhyay G, Zhou X, Gallo-way L, Farese RV. 1996. Insulin stimulates phospholipase D-dependent phosphatidylcholine hydrolysis, Rho translocation, de novo phospholipid synthesis, and diacylglycerol/protein kinase C signaling in L6 myotubes. *Endocrinology* 137: 3014-3020.
- Stauderman KA, Mahaffy LS, Akong M, Velicelebi G, Chavez-Noriega LE, Crona JH, Johnson EC, Elliott KJ, Gillespie A, Reid RT, Adams P, Harpold MM, Corey-Naeve J. 1998. Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations α2β4, α3β4 and α4β4 stably expressed in HEK293 cells. *J Pharmacol Exp Ther* 284: 777-789.
- Supino R. 1990. MTT Assay. The ERGATT/FRAME Data Bank of *In vitro* Techniques in Toxicology. Invitox, Nottingham.
- Swope SL, Moss SJ, Blackstone CD, Haganir RL. 1992. Phosphorylation of ligand-gated ion channels: a possible mode of synaptic plasticity. *FASEB J* 6: 2514-2523.
- Takai Y, Kishimoto A, Inoue M, Nishizuka Y. 1977. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian

- tissues. I. Purification and characterization of an active enzyme from bovine cerebellum. *J Biol Chem* 252: 7603-7609.
- TerBush DR, Bittner MA, Holz RW. 1988. Ca^{2+} influx causes rapid translocation of protein kinase C to membranes. Studies on the effects of secretagogues in adrenal chromaffin cells. *J Biol Chem* 263: 18873-18879.
- TerBush DR, Holz RW. 1986. Effects of phorbol esters, diglyceride, and cholinergic agonists on the subcellular distribution of protein kinase C in intact or digitonin-permeabilized adrenal chromaffin cells. *J Biol Chem* 261: 17099-17106.
- TerBush DR, Holz RW. 1990. Activation of protein kinase C is not required for exocytosis from bovine adrenal chromaffin cells. *J Biol Chem* 265: 21179-21184.
- Thomas P, Stephens M, Wilkie G, Amar M, Lunt GG, Whiting P, Gallagher T, Pereira E, Alkondon M, Albuquerque EX, Wonnacott S. 1993. (+)-Anatoxin-a is a potent agonist at neuronal nicotinic acetylcholine receptors. *J Neurochem* 60: 2308-2311.
- Thompson NT, Bonser RW, Garland LG. 1991. Receptor-coupled phospholipase D and its inhibition. *Trends Pharmacol Sci* 12: 404-408.
- Tilly BC, Lambrechts AC, Tertoolen LG, de Laat SW, Moolenaar WH. 1990. Regulation of phosphoinositide hydrolysis induced by histamine and guanine nucleotides in human HeLa carcinoma cells. Calcium and pH dependence and inhibitory role of protein kinase C. *FEBS Lett* 265: 80-84.
- Trilivas I, Brown JH. 1989. Increases in intracellular Ca^{2+} regulate the binding of [3H] phorbol 12, 13-dibutyrate to intact 1321N1 astrocytoma cells. *J Biol Chem* 264: 3102-3107.
- Trist DG, Spedding M. 1998. Calcium channels. In: IUPHAR Committee on Receptor Nomenclature and Drug Classification (ed.) *The IUPHAR Compendium of Receptor Characterization and Classification*. IUPHAR Media, London, pp 94-96.
- Tuominen RK, Hudson PM, McMillian MK, Ye H, Stachowiak MK, Hong JS. 1991. Long-term activation of protein kinase C by angiotensin II in cultured bovine adrenal medullary cells. *J Neurochem* 56: 1292-1298.
- Tuominen RK, McMillian MK, Ye H, Stachowiak MK, Hudson PM, Hong JS. 1992. Long-term activation of protein kinase C by nicotine in bovine adrenal chromaffin cells. *J Neurochem* 58: 1652-1658.
- Tuominen RK, Werner MH, Ye H, McMillian MK, Hudson PM, Hannun YA, Hong JS. 1993. Biphasic generation of diacylglycerol by angiotensin and phorbol ester in bovine adrenal chromaffin cells. *Biochem Biophys Res Commun* 190: 181-185.
- Törnquist K, Vainio P, Titievsky A, Dugue B, Tuominen R. 1999. Redox modulation of intracellular free calcium concentration in thyroid FRTL-5 cells: evidence for an enhanced extrusion of calcium. *Biochem J* 339: 621-628.
- Töröcsik A, Chaudhry IA, Biro K, Nagashima H, Kinjo M, Duncalf D, Nagashima R, Foldes FF, Goldiner PL, Vizi ES. 1989. In vitro comparison of the neuromuscular antinicotinic and intestinal antimuscarinic effects of different nondepolarizing muscle relaxants. *Arch Int Pharmacodyn* 299: 247-253.
- Unsicker K, Müller TH. 1981. Purification of bovine adrenal chromaffin cells by differential plating. *J Neurosci Methods* 4: 227-241.
- Valverde AM, Sinnott-Smith J, Van Lint J, Rozengurt E. 1994. Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain. *Proc Natl Acad Sci (USA)* 91: 8572-8576.
- Venable ME, Obeid LM. 1999. Phospholipase D in cellular senescence. *Biochim Biophys Acta* 1439: 291-298.
- Vernier JM, El-Abdellaoui H, Holsenback H, Cosford ND, Bleicher L, Barker G, Bontempi B, Chavez-Noriega L, Menzaghi F, Rao TS, Reid R, Saccaan AI, Suto C, Washburn M, Lloyd GK, McDonald IA. 1999. 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. *J Med Chem* 42: 1684-1686.
- Vizi ES, Sershen H, Balla A, Mike Á, Windish K, Jurányi Z, Lajtha A. 1995. Neurochemical evidence of heterogeneity of presynaptic and somatodendritic nicotinic acetylcholine receptors. *Ann N Y Acad Sci* 757: 84-99.
- Wada A, Uezono Y, Arita M, Tsuji K, Yanagihara N, Kobayashi H, Izumi F. 1989. High-affinity and selectivity of neosurugatoxin for the inhibition of ^{22}Na influx via nicotinic receptor-ion channel in cultured bovine adrenal medullary cells: comparative study with histrionicotoxin. *Neuroscience* 33: 333-339.
- Wang F, Gerzanich V, Wells G, Anand R, Peng X, Keyser K, Lindstrom J. 1996. Assembly of human neuronal nicotinic receptor $\alpha 5$ subunits with $\alpha 3$, $\beta 2$, and $\beta 4$ subunits. *J Biol Chem* 271: 17656-17665.
- Wang YM, Seibenhener ML, Vandenplas ML, Wooten MW. 1999. Atypical PKC ζ is activated by ceramide, resulting in coactivation of NF- κ B/JNK kinase and cell survival. *J Neurosci Res* 55: 293-302.
- Ward JM, Cockroft VB, Lunt GG, Smillie FS, Wonnacott S. 1990. Methyllycaconitine: a selective probe for neuronal α -bungarotoxin binding sites. *FEBS Lett* 270: 45-48.
- Watling KJ (ed). 1998. *The RBI Handbook of Receptor Classification and Signal Transduction*, 3 edn. RBI, Natick, MA, USA.
- Watson S, Girdlestone D (ed). 1993. *TiPS Receptor Nomenclature Supplement*, 4th edn. Elsevier, Cambridge.

- Watson S, Girdlestone D (ed). 1995. *TiPS Receptor and Ion Channel Nomenclature Supplement*, 6th edn. Elsevier, Cambridge.
- Waymire JC, Bennett WF, Boehme R, Hankins L, Gilmer-Waymire K, Haycock JW. 1983. Bovine adrenal chromaffin cells: high-yield purification and viability in suspension culture. *J Neurosci Methods* 7: 329-351.
- Wenger BW, Bryant DL, Boyd RT, McKay DB. 1997. Evidence for spare nicotinic acetylcholine receptors and a $\beta 4$ subunit in bovine adrenal chromaffin cells: studies using bromoacetylcholine, epibatidine, cytisine and mAb35. *J Pharmacol Exp Ther* 281: 905-913.
- Wetsel WC, Wasiuddin AK, Merchenthaler I, Rivera H, Halpern AE, Phung HM, Negro-Vilar A, Hannun YA. 1992. Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. *J Cell Biol* 117: 121-133.
- Whiteaker P, Sharples CGV, Wonnacott S. 1998. Agonist-induced up-regulation of $\alpha 4\beta 2$ nicotinic receptors in M10 cells: pharmacological and spatial definition. *Mol Pharmacol* 53: 950-962.
- Wilson SP. 1987. Purification of adrenal chromaffin cells on Renografin gradients. *J Neurosci Methods* 19: 163-171.
- Wilson SP, Viveros OH. 1981. Primary culture of adrenal medullary chromaffin cells in a chemically defined medium. *Exp Cell Res* 133: 159-169.
- Wood SC, Forman SA, Miller KW. 1991. Short chain and long chain alkanols have different sites of action on nicotinic acetylcholine receptor channels from *Torpedo*. *Mol Pharmacol* 39: 332-338.
- Wright TM, Rangan LA, Shin HS, Raben DM. 1988. Kinetic analysis of 1,2-diacylglycerol mass levels in cultured fibroblasts. *J Biol Chem* 263: 9374-9380.
- Xiao Y, Meyer EL, Thompson JM, Surin A, Wroblewski J, Kellar KJ. 1998. Rat $\alpha 3/\beta 4$ subtype of neuronal nicotinic acetylcholine receptor stably expressed in a transfected cell line: pharmacology of ligand binding and function. *Mol Pharmacol* 54: 322-333.
- Xie Y, Lane WV, Loring RH. 1993. Nereistoxin: a naturally occurring toxin with redox effects on neuronal nicotinic acetylcholine receptors in chick retina. *J Pharmacol Exp Ther* 264: 689-694.
- Xie Y, McHugh T, McKay J, Jones GSJ, Loring RH. 1996. Evidence that a nereistoxin metabolite, and not nereistoxin itself, reduces neuronal nicotinic receptors: studies in the whole chick ciliary ganglion, on isolated neurons and immunoprecipitated receptors. *J Pharmacol Exp Ther* 276: 169-177.
- Xu Y, Duarte EP, Forsberg EJ. 1992. Role of thapsigargin-sensitive intracellular Ca^{2+} pools in secretion induced by muscarinic agonists in porcine adrenal chromaffin cells. *J Neurochem* 59: 2224-2229.
- Yamagami K, Nishimura S, Sorimachi M. 1991. Internal Ca^{2+} mobilization by muscarinic stimulation increases secretion from adrenal chromaffin cells only in the presence of Ca^{2+} influx. *J Neurochem* 57: 1681-1689.
- Yamazaki H, Inoue K, Hashimoto M, Shimada T. 1999. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. *Arch Toxicol* 73: 65-70.
- Zhou Z, Neher E. 1993. Calcium permeability of nicotinic acetylcholine receptor channels in bovine adrenal chromaffin cells. *Pflügers Archiv* 425: 511-517.